<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">04640</article-id><article-id pub-id-type="doi">10.7554/eLife.04640</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-17200"><name><surname>Korkut</surname><given-names>Anil</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataro1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-19320"><name><surname>Wang</surname><given-names>Weiqing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataro1"/></contrib><contrib contrib-type="author" id="author-19321"><name><surname>Demir</surname><given-names>Emek</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19322"><name><surname>Aksoy</surname><given-names>Bülent Arman</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19323"><name><surname>Jing</surname><given-names>Xiaohong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19324"><name><surname>Molinelli</surname><given-names>Evan J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19325"><name><surname>Babur</surname><given-names>Özgün</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19326"><name><surname>Bemis</surname><given-names>Debra L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32042"><name><surname>Onur Sumer</surname><given-names>Selcuk</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-5507"><name><surname>Solit</surname><given-names>David B</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19327"><name><surname>Pratilas</surname><given-names>Christine A</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-14392"><name><surname>Sander</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataro1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Computational Biology Center</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution>Tri-Institutional Training Program in Computational Biology and Medicine</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Human Oncology and Pathogenesis Program</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Medicine</institution>, <institution>Memorial Sloan Kettering Cancer Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><label>5</label><institution>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-16436"><name><surname>Airoldi</surname><given-names>Edoardo M</given-names></name><role>Reviewing editor</role><aff><institution>Harvard University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">For correspondence: <email>bpmel@sanderlab.org</email> (AK, WW, CS)</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>08</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e04640</elocation-id><history><date date-type="received"><day>10</day><month>09</month><year>2014</year></date><date date-type="accepted"><day>07</day><month>07</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Korkut et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Korkut et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-04640-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.04640.001</object-id><p>Resistance to targeted cancer therapies is an important clinical problem. The discovery of anti-resistance drug combinations is challenging as resistance can arise by diverse escape mechanisms. To address this challenge, we improved and applied the experimental-computational perturbation biology method. Using statistical inference, we build network models from high-throughput measurements of molecular and phenotypic responses to combinatorial targeted perturbations. The models are computationally executed to predict the effects of thousands of untested perturbations. In RAF-inhibitor resistant melanoma cells, we measured 143 proteomic/phenotypic entities under 89 perturbation conditions and predicted c-Myc as an effective therapeutic co-target with BRAF or MEK. Experiments using the BET bromodomain inhibitor JQ1 affecting the level of c-Myc protein and protein kinase inhibitors targeting the ERK pathway confirmed the prediction. In conclusion, we propose an anti-cancer strategy of co-targeting a specific upstream alteration and a general downstream point of vulnerability to prevent or overcome resistance to targeted drugs.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.001">http://dx.doi.org/10.7554/eLife.04640.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.04640.002</object-id><title>eLife digest</title><p>Drugs that target the activity of specific genes could potentially form precise cancer therapies. Some cancers, including the aggressive skin cancer called melanoma, initially respond well to such treatments. However, resistance to drugs develops quickly, leading to the rapid regrowth of the tumors.</p><p>Resistance can develop in a number of ways. For example, to prevent the drug from working or to compensate for the effects of a drug, cancer cells can adapt their signaling processes or acquire genetic mutations or other modifications that affect how genes are expressed.</p><p>A well-designed combination of drugs that targets multiple molecular pathways can make it harder for cells to resist treatment, as this limits the number of available ‘escape’ pathways that bypass the drug targets. However, it is difficult to accurately predict how a cell will respond when treated with a particular drug, making it extremely challenging to design effective drug combinations.</p><p>In 2013, researchers developed a technique to build predictive models of cellular response pathways based on data collected from perturbation experiments followed by mathematical modeling. Now, Korkut et al.—including several of the researchers involved in the 2013 work—have refined this technology and applied it to the problem of preventing drug resistance in cancer cells.</p><p>Computer simulations that used the mathematical models suggested a particular strategy of ‘upstream–downstream targeting’ in cells that were insensitive to the clinically successful drug vemurafenib (an inhibitor of RAF proteins, which are often mutated in cancers). In the landscape of signaling pathways, the target of the upstream drug is on or near the mutated RAF protein. c-Myc, the indirect target of the downstream drug helps to express genes that trigger signals that cause the cells to grow. Inhibiting both targets in parallel may have the dual advantage of blocking the activation of the tumor-specific growth pathway while reducing the cancer cells' attempts to bypass the activation block.</p><p>An initial test of the designed drug combination required moving from computer simulations to the laboratory using cell cultures originally derived from melanoma tumors. When Korkut et al. applied the drug combination, the combined treatment successfully blocked cell growth. The results suggest that the data-driven computer modeling strategy termed perturbation biology could be a useful tool for identifying effective cancer drug combinations for further preclinical research, possibly followed by clinical trials.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.002">http://dx.doi.org/10.7554/eLife.04640.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>network modeling</kwd><kwd>drug synergy</kwd><kwd>cancer drug resistance</kwd><kwd>proteomics</kwd><kwd>cellular signaling</kwd><kwd>melanoma</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health (NIH)</institution></institution-wrap></funding-source><award-id>The National Resource for Network Biology grant, GM 103504</award-id><principal-award-recipient><name><surname>Korkut</surname><given-names>Anil</given-names></name><name><surname>Demir</surname><given-names>Emek</given-names></name><name><surname>Babur</surname><given-names>Özgün</given-names></name><name><surname>Sander</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000051</institution-id><institution>National Human Genome Research Institute (NHGRI)</institution></institution-wrap></funding-source><award-id>The Research Resource for Biological Pathways grant, U41 HG006623</award-id><principal-award-recipient><name><surname>Demir</surname><given-names>Emek</given-names></name><name><surname>Babur</surname><given-names>Özgün</given-names></name><name><surname>Sander</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005190</institution-id><institution>Melanoma Research Alliance (MRA)</institution></institution-wrap></funding-source><award-id>Established Investigator Award</award-id><principal-award-recipient><name><surname>Korkut</surname><given-names>Anil</given-names></name><name><surname>Wang</surname><given-names>Weiqing</given-names></name><name><surname>Sander</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health (NIH)</institution></institution-wrap></funding-source><award-id>Center for Cancer Systems Biology grant, U54 CA148967</award-id><principal-award-recipient><name><surname>Korkut</surname><given-names>Anil</given-names></name><name><surname>Wang</surname><given-names>Weiqing</given-names></name><name><surname>Sander</surname><given-names>Chris</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.3</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Data-driven systems biology models of signaling predict cellular response to untested perturbations and can nominate drug combinations to overcome drug resistance in cancer cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><sec id="s1-1"><title>Drug resistance in cancer treatment</title><p>The inhibition of key oncogenes with target-specific agents elicits dramatic initial response in some cancers such as prostate cancer and melanoma (<xref ref-type="bibr" rid="bib4">Bollag et al., 2010</xref>; <xref ref-type="bibr" rid="bib11">Clegg et al., 2012</xref>). Even for the most successful single-agent targeted therapies, however, drug resistance eventually emerges leading to rapid progression of metastatic disease (<xref ref-type="bibr" rid="bib23">Garraway and Janne, 2012</xref>). The mechanism of drug resistance may involve selection of resistant sub-clones, emergence of additional genomic alterations, and compensating interactions between alternative signaling pathways (<xref ref-type="bibr" rid="bib9">Choi et al., 2007</xref>; <xref ref-type="bibr" rid="bib26">Huang et al., 2011</xref>; <xref ref-type="bibr" rid="bib65">Wagle et al., 2013</xref>). One potential solution to overcome drug resistance is to combine targeted drugs to block potential escape routes (<xref ref-type="bibr" rid="bib20">Fitzgerald et al., 2006</xref>). Therefore, there is currently a need for systematic strategies to develop effective drug combinations.</p></sec><sec id="s1-2"><title>Drug resistance in melanoma</title><p>Targeted therapy has been particularly successful in treatment of melanoma. <italic>BRAFV600E</italic> gain-of-function mutation is observed in ∼50% of melanomas (<xref ref-type="bibr" rid="bib13">Davies et al., 2002</xref>). Direct inhibition of BRAFV600E by the RAF inhibitor (RAFi) vemurafenib and inhibition of the downstream MEK and ERK kinases have yielded response rates of more than 50% in melanoma patients with this mutation (<xref ref-type="bibr" rid="bib7">Chapman et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Flaherty et al., 2012b</xref>). At the cellular level, inhibition of the ERK pathway leads to changes in expression of a set of critical cell cycle genes (e.g., <italic>CCND1, MYC, FOS</italic>) and feedback inhibitors of ERK signaling (e.g., <italic>DUSP, SPRY2</italic>) (<xref ref-type="bibr" rid="bib49">Pratilas et al., 2009</xref>). Resistance to vemurafenib emerges after a period of ∼7 months in tumors that initially responded to single-agent therapy (<xref ref-type="bibr" rid="bib7">Chapman et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Sosman et al., 2012</xref>). Multiple RAFi and MEKi (e.g., PD-0325901, Trametinib) resistance mechanisms, which may involve alterations in NRAS/ERK pathway (e.g., NRAS mutations, switching between RAF isoforms) or parallel pathways (e.g., PTEN loss), have been discovered in melanoma (<xref ref-type="bibr" rid="bib28">Johannessen et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Nazarian et al., 2010</xref>; <xref ref-type="bibr" rid="bib47">Poulikakos et al., 2010</xref>; <xref ref-type="bibr" rid="bib67">Xing et al., 2012</xref>).</p><p>The alterations associated with drug resistance may pre-exist alone, in combinations, or emerge sequentially and vary substantially between patients (<xref ref-type="bibr" rid="bib63">Van Allen et al., 2014</xref>). Effective drug combinations may target diverse resistance mechanisms. Despite anecdotal success, conventional methods and combinatorial drug screens generally fail to come up with effective combinations due to the genomic complexity and heterogeneity of tumors (<xref ref-type="bibr" rid="bib68">Zhao et al., 2014</xref>). In order to more effectively nominate drug combinations, we propose to employ system-wide models that cover interactions between tens to hundreds of signaling entities and can describe and predict cellular response to multiple interventions. There have been prior attempts to construct such signaling models. De novo and data-driven quantitative models were able to cover only a few signaling interactions and therefore had limited predictive power (<xref ref-type="bibr" rid="bib42">Nelander et al., 2008</xref>; <xref ref-type="bibr" rid="bib3">Bender et al., 2011</xref>; <xref ref-type="bibr" rid="bib29">Klinger et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Oates et al., 2014</xref>). Qualitative or discrete models can cover more interactions but typically lack the capability of generating quantitative predictions (<xref ref-type="bibr" rid="bib52">Saez-Rodriguez et al., 2009</xref>; <xref ref-type="bibr" rid="bib5">Breitkreutz et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Saez-Rodriguez et al., 2011</xref>). Detailed physicochemical models derived using generic biochemical kinetics data can be quite comprehensive and quantitative but typically lack sufficient cell-type specificity required for translationally useful predictions (<xref ref-type="bibr" rid="bib8">Chen et al., 2009</xref>).</p><p>We construct comprehensive, cell-type specific signaling models that quantitatively link drug perturbations, (phospho)proteomic changes, and phenotypic outcomes (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The models capture diverse signaling events and predict cellular response to previously untested combinatorial interventions. In order to generate the training data for network modeling, we first perform systematic perturbation experiments in cancer cells with targeted agents. Next, we profile proteomic and phenotypic response of cells to the perturbations. The cell-type specific response data serve as the input for network inference. In this study, we also incorporate prior pathway information from signaling databases to narrow the parameter search space and improve the accuracy of the models. For this purpose, we developed a computational tool (Pathway Extraction and Reduction Algorithm [PERA]) that automatically extracts priors from the Pathway Commons signaling information resource (<xref ref-type="bibr" rid="bib16">Demir et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Cerami et al., 2011</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.003</object-id><label>Figure 1.</label><caption><title>Quantitative and predictive signaling models are generated from experimental response profiles to perturbations.</title><p>Perturbation biology involves systematic perturbations of cells with combinations of targeted compounds (Box 1, 2), high-throughput measurements of responses (Box 2), automated extraction of prior signaling information from databases (Box 3, 4), construction of ordinary differential equation (ODE)-based signaling pathway models (Box 5 and <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>) with the belief propagation (BP) based network inference algorithm (Box 6), and prediction of system responses to novel perturbations with the models and simulations (Box 7) (<xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al., 2013</xref>). The newly developed ‘Pathway Extraction and Reduction Algorithm’ (PERA) (Box 3) generates a qualitative prior model (Box 4), which is a network of known interactions between the proteins of interest (i.e., profiled (phospho)proteins). This is achieved through a search in the Pathway Commons information resource, which integrates biological pathway information from multiple public databases. In the quantitative network models, the nodes represent measured levels of (phospho)proteins or cellular phenotypes, and the edges represent the influence of the upstream nodes on the time derivative of their downstream effectors. This definition corresponds to a simple yet efficient ODE-based mathematical description of models (Box 5). Our BP-based modeling approach combines information from the perturbation data (phosphoproteomic and phenotypic) with prior information to generate network models of signaling (Box 6). We execute the resulting ODE-based models to predict system response to untested perturbation conditions (Box 7).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.003">http://dx.doi.org/10.7554/eLife.04640.003</ext-link></p></caption><graphic xlink:href="elife-04640-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>BP-guided decimation algorithm.</title><p>The algorithm is used to construct executable, individual network model solutions from BP-generated probability distributions for each edge strength value (W<sub>ij</sub>). The algorithm chart depicts one round of BP-guided decimation to generate a single model solution. Consecutive runs of BP-guided decimation algorithm lead to construction of a network model solution ensemble.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.004">http://dx.doi.org/10.7554/eLife.04640.004</ext-link></p></caption><graphic xlink:href="elife-04640-fig1-figsupp1-v1.tif"/></fig></fig-group></p><p>Even in the presence of large training data and priors, network inference is a difficult problem due to the combinatorial complexity (i.e., exponential expansion of the parameter search space with linear increase of parameters). For example, to infer a network model with 100 nodes using Monte Carlo-based methods, we in principle would need to cover a search space that includes ∼2<sup>(100 × 100)</sup> network models—a computationally impossible task. To circumvent this problem, we previously had developed a network modeling algorithm based on belief propagation (BP), which replaces exhaustive one-by-one searches over many individual network models by a search over probability distributions representing sets of low-error network models (<xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al., 2013</xref>). The algorithm enables us to construct models that can predict response of hundreds of signaling entities to any perturbations in the space of modeled components. Here, we improved the perturbation biology method through automated incorporation of prior information (signaling interactions from databases) to obtain more accurate network models. The prior information is extracted from the signaling databases using the newly developed PERA tool. To improve predictive power and preserve cell-type specificity, we use prior information as soft restraints on search space through use of a probabilistic error model of priors, that is, the algorithm rejects interactions that do not conform to the experimental training data and predicts novel interactions not sampled in the priors (see <xref ref-type="disp-formula" rid="equ3">Equations 2</xref>–<xref ref-type="disp-formula" rid="equ7">7</xref>). To derive richer and more informative network models, we also scaled up the implementation to deal with a larger number of proteomic and phenotypic nodes (see ‘Materials and methods’ for details and comments on potential future opportunities in perturbation biology). To quantitatively predict cellular response to combinatorial perturbations, we simulate the fully parameterized network models with in silico perturbations until the system reaches steady state (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The steady-state readout for each proteomic and phenotypic entity (i.e., system variables) is the predicted response to the perturbations.</p><p>In this study, we improved and applied the perturbation biology method to devise a potentially generalizable strategy for overcoming resistance to targeted cancer therapies. We constructed cell-type specific network models of signaling from perturbation experiments in RAFi-resistant melanoma cells (SkMel-133 cell line). The melanoma cells used for network modeling have a <italic>BRAFV600E</italic> mutation and homozygous deletions in <italic>PTEN</italic> and <italic>CDKN2A</italic>. The models quantitatively link 82 (phospho)proteomic nodes (i.e., molecular concentrations) and 12 protein activity nodes with 5 cellular phenotype nodes (e.g., cell viability). As shown by cross-validation calculations, use of prior information significantly improved the predictive power of the models. Once the predictive power was established, we expanded the extent of the drug response information from a few thousand experimental data points to millions of predicted node values. Based on the predictions, which cannot be trivially deduced from experimental data, we nominated co-targeting of c-Myc and BRAF or MEK as a potential strategy to overcome RAFi-resistance. To test the prediction, we first experimentally showed that the BET bromodomain inhibitor, JQ1, reduces c-Myc expression. Next, we showed that JQ1 blocks the growth of RAFi-resistant SkMel-133 cells in synergy with RAF/MEK signaling inhibition, and in this context, overcomes the drug resistance. Based on these results, we put forward the falsifiable hypothesis that co-targeting a specific upstream alteration and a general downstream point of vulnerability is a good strategy to prevent or overcome resistance to targeted drugs.</p></sec></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Experimental response maps from proteomic/phenotypic profiling</title><sec id="s2-1-1"><title>Drug perturbation experiments in melanoma cells</title><p>We performed systematic perturbation experiments in malignant melanoma cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) to generate a rich training set for network inference. The RAFi-resistant melanoma cell line SkMel-133 was treated with combinations of 12 targeted drugs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, see <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1A</xref> for drug targets and doses, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1C</xref> for all perturbation conditions). The perturbations consisted of systematic paired combinations and multiple doses of single agents. This procedure generated 89 unique perturbation conditions, which targeted specific pathways including those important for melanoma tumorigenesis such as ERK and PI3K/AKT (<xref ref-type="bibr" rid="bib24">Haluska et al., 2006</xref>).<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.008</object-id><label>Figure 2.</label><caption><title>Response of melanoma cells to systematic perturbations with targeted agents.</title><p>(<bold>A</bold>) The combinatorial perturbation matrix. The melanoma cells are perturbed with combinations of targeted drugs (see <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1C</xref> for perturbation conditions). (<bold>B</bold>) The concentration changes in 138 proteomic entities (50 phospho, 88 total protein measurements) (left) and the phenotypic changes (right) in response to drug combinations with respect to the untreated conditions form an experimental ‘response map’ of the cellular system. The response map reflects the functional relations between signaling proteins and cellular processes. The two-way clustering analysis of the proteomic readouts reveals distinct proteomic response signatures for each targeted drug. Phosphoproteomic response is measured using the RPPA technology. Cell cycle progression and viability response are measured using flow cytometry and resazurin assays, respectively. The cell cycle progression phenotype is quantified based on the percentage of the cells in a cell cycle state in perturbed condition with respect to the unperturbed condition. For the phenotypic readouts, the order of the perturbation conditions is same as in (<bold>A</bold>). The response values are relative to a no drug control and given as log<sub>2</sub>(perturbed/unperturbed).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.008">http://dx.doi.org/10.7554/eLife.04640.008</ext-link></p></caption><graphic xlink:href="elife-04640-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.009</object-id><label>Figure 2—figure supplement 1.</label><caption><title>The two-way clustering analysis of the experimental response map.</title><p>The hierarchical clustering reveals distinct proteomic signatures of response to drugs targeting different signaling pathways. The Cluster software is used for the two-way hierarchical clustering with correlation-based distance metric and average-linkage method. We identified three major (C1, C2, and C4) and three minor (C3, C5, C6) proteomic response clusters.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.009">http://dx.doi.org/10.7554/eLife.04640.009</ext-link></p></caption><graphic xlink:href="elife-04640-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.010</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Cluster-guided pathway analysis of the response map.</title><p>We extracted the signaling interactions between the proteomic entities that fell into each cluster. The signaling interactions within each proteomic cluster are extracted from the Pathway Commons 2 database using the PERA algorithm. Here, we simplified the pathway diagrams by removing the post-translational modifications and merging the nodes associated with identical genes (e.g., AKTpT308, AKTpS473, and AKT are merged to AKT node). The resulting diagrams display the known pathways associated with proteomic response clusters. The cluster-guided pathway analysis suggests that functionally related proteins (i.e., proteins on the same or related pathways) are enriched in distinct clusters. The phospho-proteomic entities on MAPK and PI3K/AKT pathways are enriched in cluster 1 (C1) of the response map. The total protein measurements related to MAPK and PI3K/AKT pathways are enriched in a related but distinct cluster (C2). The level of various apoptotic proteins increase in response to most targeted drugs and form another distinct cluster (C4). Interestingly, EGFR (Both phospho and total level) and a set of EGFR related docking proteins (e.g., SHC, 14-3-3-β) are also enriched in C4 possibly due to the increase in the expression of those entities in response to targeted drugs such as MEKi and PI3Ki. The observed increase in EGFR level suggests a potential feedback loop that emerges from downstream elements of MAPK and PI3K/AKT pathways, which are targeted by multiple agents in this study.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.010">http://dx.doi.org/10.7554/eLife.04640.010</ext-link></p></caption><graphic xlink:href="elife-04640-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.011</object-id><label>Figure 2—figure supplement 3.</label><caption><title>Proteomic response to single agent perturbations.</title><p>Proteomic levels in SkMel-133 cells change in response to targeted drugs as measured with reverse phase protein array (RPPA). For each drug, we listed the top 10 decreasing and increasing phosphoproteins out of 138 proteomic entities profiled with RPPA. The protein levels are normalized to no drug condition and given in linear space.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.011">http://dx.doi.org/10.7554/eLife.04640.011</ext-link></p></caption><graphic xlink:href="elife-04640-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.012</object-id><label>Figure 2—figure supplement 4.</label><caption><title>Association models of the response map from partial correlations.</title><p>A correlation-based network model of signaling is inferred using the SkMel-133 perturbation response data and the graphical Gaussian model (GGM) network inference method. GGM uses the first-order partial correlation coefficients as a measure of direct associations between two nodes, for which the effects of other nodes are eliminated. The advantage of partial correlations over the conventional pairwise correlations is its ability to distinguish direct interactions from indirect ones. Partial coefficients are calculated by inverting the correlation matrix. Here, we computed the partial correlations using the shrinkage estimation method, a form of regularized estimator of the covariance matrix and its inverse (<xref ref-type="bibr" rid="bib55">Schafer and Strimmer, 2005</xref>). Shrinkage method is particularly useful for inferring models when number of variables is higher than number of constraints (n &gt; p). See (<xref ref-type="bibr" rid="bib55">Schafer and Strimmer, 2005</xref>) for algorithmic details and formulation of partial correlation calculation. The network model covers the interactions between 138 proteomic species and five phenotypic measurements (i.e., cell viability and cell cycle progression nodes). The models involve the interactions with statistically significant (False Discovery Rate (FDR) -adjusted p-value &lt; 0.01, H0: pcor = 0 based on a null-distribution estimated from the data, see <xref ref-type="bibr" rid="bib55">Schafer and Strimmer, 2005</xref>, for details) association strengths (green: positive, red: negative associations). The resulting models capture some of the well-characterized and potentially interesting interactions such as those between AKT, GSK3, and TSC2. Cell viability node is directly linked to proteomic nodes SMAD3, Cyclin E1, MGMT. G1-arrest node is directly linked to MEK phosphorylation node, while S-arrest is associated with beta-catenin phosphorylation node. G2-arrest is linked to STAT3 and caveolin total levels, and G2M transition is linked to BRAF, RB, and p90S6K total level nodes. The models provide an approximate picture of pairwise interactions in SkMel-133 cells, are not executable, do not capture the high-order couplings within the cellular system, and hence, we conclude that they do not have the required power for predicting system response to untested perturbations.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.012">http://dx.doi.org/10.7554/eLife.04640.012</ext-link></p></caption><graphic xlink:href="elife-04640-fig2-figsupp4-v1.tif"/></fig></fig-group></p></sec><sec id="s2-1-2"><title>Proteomic/phenotypic profiles</title><p>A key aspect of the data acquisition for network inference is combining the proteomic and cellular phenotypic data so that the resulting models quantitatively link the proteomic changes to global cellular responses. Toward this objective, we profiled the melanoma cells for their proteomic and phenotypic response under 89 perturbation conditions (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). We used reverse phase protein arrays (RPPA) to collect drug response data for 138 proteomic (total- and phospho-protein levels) entities in all conditions (<xref ref-type="bibr" rid="bib62">Tibes et al., 2006</xref>). In parallel, we measured phenotypic responses, including cell viability and cell cycle progression (i.e., G1, S, G2, G2M arrest phenotypes) in all conditions (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p></sec><sec id="s2-1-3"><title>The response map</title><p>The high-throughput phenotypic and proteomic profiles form a response map of cells to systematic perturbations (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The response map provides context-specific experimental information on the associations between multiple system variables (i.e., proteomic entities) and outputs (i.e., phenotypes) under multiple conditions (i.e., perturbations). We demonstrate through hierarchical clustering of the map that each targeted drug induces a distinct proteomic response, and drugs targeting the same pathway lead to overlapping responses in the SkMel-133 cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Through a clustering-driven pathway analysis, we further show that functionally related proteins (i.e., proteins on same or related pathways) respond similarly to targeted agents (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1 fig2s2 fig2s3">Figure 2—figure supplements 1–3</xref>).</p><p>The response map can be described as a set of uncoupled pairwise associations between proteomic and phenotypic entities. We provide an example of an association network model (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). The association network was inferred using the experimental response map (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and graphical Gaussian models, which utilizes partial correlations for network inference (<xref ref-type="bibr" rid="bib55">Schafer and Strimmer, 2005</xref>). Such models, however, are not sufficient for achieving systematic predictions as they do not capture the nonlinear nature of the couplings between the entities and cannot be executed with in silico perturbations. Therefore, we built quantitative models using the experimental response map. The resulting models describe the coupled nature of the interactions between proteins and cellular events, as well as the nonlinear dynamics of cellular responses to drug perturbations.</p></sec></sec><sec id="s2-2"><title>Quantitative and predictive network models of signaling</title><sec id="s2-2-1"><title>Network models</title><p>Next, we used the experimental response map (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and the BP-based inference strategy (<xref ref-type="fig" rid="fig1">Figure 1</xref>) to build quantitative network models of signaling in melanoma. In the models, each node quantifies the relative response of a proteomic or phenotypic entity to perturbations with respect to the basal condition. Consequently, proteomic entities that do not respond to even a single perturbation condition, do not contribute any constraints for inference. We eliminated such entities from the network modeling with a signal-to-noise analysis and included 82 of the 138 proteomic measurements in the modeling (see ‘Materials and methods’, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1B</xref>). In addition to the proteomic nodes, the models contained 5 phenotypic nodes and 12 ‘activity nodes’, which represent the 12 drugs and couple the effects of the targeted perturbations to the other nodes in the network. In total, network models contained 99 nodes. BP algorithm generates the probability distribution of edge strengths for every possible interaction between the nodes. The BP-guided decimation algorithm (see ‘Materials and methods’, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) instantiates distinct network model configurations from the probability model (<xref ref-type="bibr" rid="bib39">Montanari et al., 2007</xref>).</p><p>The mathematical formulation of the BP-based network inference is suitable for both de novo modeling (i.e., modeling with no prior information) and modeling using prior information (see ‘Materials and methods’). Here, we used prior information to infer models with higher accuracy and predictive power compared to de novo models. Using the PERA computational tool, we derived a generic prior information model from Reactome and NCI-Nature PID databases, which were stored in Pathway Commons (<xref ref-type="bibr" rid="bib6">Cerami et al., 2011</xref>). The prior information network contains 154 interactions spanning multiple pathways (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Next, we added a prior prize term to the error model (<xref ref-type="disp-formula" rid="equ3">Equation 2</xref>) to restrain the search space by favoring the interactions in the prior model. It is critical that the prior information does not overly restrain the inferred models and the algorithm can reject incorrect priors. To address this problem, we inferred network models using the pathway driven and randomly generated prior restraints. The statistical comparison of the networks inferred with actual (i.e., reported in databases) and random prior models indicated that the inference algorithm rejected a significantly higher number of prior interactions when randomly generated priors were used for modeling (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Finally, we integrated the experimental data and prior information to generate 4000 distinct and executable model solutions with low errors (i.e., sets of model parameters, <bold>W</bold><sub><bold>ij</bold></sub>, for which the model equations best reproduce the experimental response map) using the BP-based strategy.</p></sec></sec><sec id="s2-3"><title>Use of prior information improves the predictive power of models</title><sec id="s2-3-1"><title>Cross validations with and without prior information</title><p>We addressed the question whether BP-derived models have predictive power and whether use of prior information introduces further improvement. To assess the predictive power of the network models (i.e., predicting the response to untested perturbations), we performed a leave-k-out cross validation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). In each validation calculation, we withheld the response profile to every combination of a particular drug (e.g., RAFi) and all other drugs (leave-11-out cross validation) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). For each cross-validation calculation, this procedure created a partial training data set that contains response to combinations of 11 drugs and two different doses of a single drug totaling to 78 unique conditions (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1B,C</xref>).<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.013</object-id><label>Figure 3.</label><caption><title>Use of prior information increases the predictive power of models.</title><p>(<bold>A</bold>) To test the predictive power of network models, a leave-11-out cross-validation test is performed. Using the BP-guided decimation algorithm, 4000 network model solutions are inferred in the presence and absence of prior information using the partial response data. Resulting models are executed with in silico perturbations to predict the withheld conditions. Each experimental data point represents the readouts from RPPA and phenotype measurements under the corresponding perturbation conditions. Each predicted data point is obtained by averaging results from simulations with in silico perturbations over 4000 model solutions. The experimental and predicted profiles are compared to demonstrate the power of network models to predict response to combinatorial drug perturbations. (<bold>B</bold>) In all conditions, network inference with prior information leads to a higher cumulative correlation coefficient (R) and significantly improved prediction quality (RAFi p = 1 × 10<sup>−3</sup>, AKTi p = 5.7 × 10<sup>−3</sup>, unpaired t-test H<sub>0</sub>: ΔX<sup>with_prior</sup> = ΔX<sup>w/o_prior</sup>, ΔX = |X<sub>exp</sub> − X<sub>pred</sub>|) between experimental and predicted responses. Plots on top row: prior information is used for network inference. Plots on bottom row: no prior information is used for network inference. Response to RAFi + {D<sub>i</sub>} (first and second column) and AKTi + {D<sub>i</sub>} (third and fourth column) is withheld from the training set and the withheld response is predicted. All responses (phenotypic + proteomic) (first and third column) and only phenotypic responses (second and fourth column) are plotted. {D<sub>i</sub>} denotes set of all drug perturbations combined with drug of interest. (See <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> for the cross-validation calculations with all other partial data sets and <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref> for statistical validation of the predictions.)</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.013">http://dx.doi.org/10.7554/eLife.04640.013</ext-link></p></caption><graphic xlink:href="elife-04640-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.014</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Predictive power of the perturbation biology models.</title><p>The ability of the models to predict system response to untested perturbations is tested with a leave-11-out cross-validation scheme, which involves model simulations with in silico perturbations (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). For each cross-validation calculation, the response profile to every possible combination of an individual drug is withheld and models are constructed using the partial data (i.e., combinations of all other drugs plus the drug of interest applied as a single agent) and prior information. Through simulations of the models with in silico perturbations that represent the withheld experimental perturbations, we predict the system response in the withheld conditions. The comparison of the simulated data with the experimental data reveals the predictive power (ability of the models to predict system response to untested perturbations) of our modeling approach. Here, we demonstrate the cross-validation results for 10 drugs (see <xref ref-type="fig" rid="fig3">Figure 3A</xref> for RAF inhibitor [RAFi] and AKTi cross-validation results). In each plot, Di represents all drugs except the drug, for which all combinatorial drug response is withheld. For each validation calculation displayed in this figure, 1000 models are generated using the BP-guided decimation algorithm. Each model is executed with 11 in silico perturbations (e.g., mTORi + Di). The simulation results are averaged over 1000 models for each proteomic and phenotypic node and compared to the experimentally measured values. R represents the correlation between the experimental and the predicted response data. To statistically validate the predictions, we computed the frequentist coverage probability for each calculation (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.014">http://dx.doi.org/10.7554/eLife.04640.014</ext-link></p></caption><graphic xlink:href="elife-04640-fig3-figsupp1-v1.tif"/></fig></fig-group></p><p>First, we constructed both de novo (i.e., without any prior information) and prior information guided network models using two partial data sets from which responses to combinations of drugs with RAFi or AKTi were withheld. Next, we predicted the response by executing the models with in silico perturbations that corresponded to the withheld experimental conditions. Finally, we compared the hidden and predicted response data from models generated de novo or with prior information.</p></sec><sec id="s2-3-2"><title>Restraining inference with prior information improves the predictive power of models</title><p>The comparison between the predicted and the withheld experimental profiles suggests that the de novo network models have considerable predictive power, and the use of prior information in modeling introduces significant improvement in the prediction quality (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Use of prior information increased the cumulative correlation coefficient between predicted and experimental response data from 0.72 to 0.84 and from 0.71 to 0.81 for RAFi and AKTi, respectively. The demonstrated predictive power of the models suggests that the models are suitable for systematically predicting response to perturbation combinations not sampled in the training set and generating testable hypotheses that link external perturbations (e.g., targeted drugs) to cellular response.</p></sec></sec><sec id="s2-4"><title>Network models identify context-dependent oncogenic signaling in melanoma</title><sec id="s2-4-1"><title>Network modeling and the average model</title><p>We generated quantitative network models with the complete experimental response profile and prior information to investigate oncogenic signaling in melanoma. The resulting network models resemble conventional pathway representations facilitating their comparison with the biological literature (<xref ref-type="bibr" rid="bib30">Le Novere et al., 2009</xref>), but the interaction edges do not necessarily represent physical interactions between connected nodes. Analysis of the ensemble of network model solutions reveals that a set of strong interactions is shared by a majority of the inferred network models. On the other hand, some interactions have nonzero edge strength (W<sub>ij</sub> ≠ 0) values only in a fraction of the models (see <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> for analysis of the edge distribution in models). As a first step of detailed analysis and for the purpose of intuitive interpretation, we computed an average network model (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), which is obtained by averaging the interaction strength (W<sub>ij</sub>) for each node pair, ij, over all individual model solutions. This average network model highlights the interactions with high W<sub>ij</sub> values if shared by the majority of the distinct solutions. Although the average model cannot be simulated to predict system response, it is particularly useful for qualitative analysis of the inferred signaling interactions.<fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.015</object-id><label>Figure 4.</label><caption><title>Inferred network models capture oncogenic signaling pathways in melanoma.</title><p>(<bold>A</bold>) The generation of the average model. The set of &lt;W<sub>ij</sub>&gt; averaged over the W<sub>ij</sub> in all models provide the average network model. The signaling processes are explained through qualitative analysis of the average model and its functional subnetworks (see <xref ref-type="fig" rid="fig5">Figure 5</xref> for quantitative analysis). (<bold>B</bold>) The average network model contains proteomic (white) and phenotypic nodes (orange) and the average signaling interactions (&lt;Wij&gt; &gt; 0.2) over the model solutions. The edges between the BRAF, CRAF, TSC2, and AKTpT308 represent the cross-pathway interactions between the MAPK and PI3K/AKT pathways (see <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref> for analysis of edge distributions in the solution ensemble) (green edges: positive signed, red edges: negative signed interactions). (<bold>C</bold>) Cell cycle signaling subnetwork contains the interactions between the cyclins, CDKs, and other associated molecules (e.g., p27/Kip1). RBpS807 and cyclin D1 are the hub nodes in the subnetwork and connect multiple signaling entities. (<bold>D</bold>) ERK subnetwork. MEKpS217 is the critical hub in this pathway and links upstream BRAF and SRC to downstream effectors such as ERK phosphorylation. (<bold>E</bold>) In the PI3K/AKT subnetwork, the SRC nodes (i.e., phosphorylation, total level, activity) are upstream of PI3K and AKT (total level, AKTpS473 and AKTp308) and the AKT nodes are the major hubs. Downstream of AKT, the pathway branches to mTOR, P70S6K and S6 phosphorylation cascade and the GSK3β phosphorylation events. A negative edge originating from mTORpS2448 and acting on AKTpS473 presumably captures the well-defined negative feedback loop in the AKT pathway (<xref ref-type="bibr" rid="bib44">O'Reilly et al., 2006</xref>). Note that nodes tagged with ‘a’ (e.g., aBRAFV600E) are activity nodes, which couple drug perturbations to proteomic changes.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.015">http://dx.doi.org/10.7554/eLife.04640.015</ext-link></p></caption><graphic xlink:href="elife-04640-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.016</object-id><label>Figure 4—figure supplement 1.</label><caption><title>The prior model of signaling.</title><p>The prior information model is extracted from Reactome and NCI PID using the PERA algorithm (see ‘Materials and methods’ for PERA algorithm and use of the prior model in inference). The prior model served as a bias in BP-based network inference. Green arrows represent priors for activating edges, red arrows represent inhibitory edges, and black arrows represent generic edges (i.e., activating or inhibitory).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.016">http://dx.doi.org/10.7554/eLife.04640.016</ext-link></p></caption><graphic xlink:href="elife-04640-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.017</object-id><label>Figure 4—figure supplement 2.</label><caption><title>Distribution of edges in the solution ensemble.</title><p>In order to model cellular signaling and predict response, we computed 4000 signaling models and generated a solution ensemble. Top: edge frequencies (f(w<sub>ij</sub>)) in the solution ensemble. The y-axis represents the frequency values for nonzero edge strengths (f(|w<sub>ij</sub>| &gt; 0.2)) in the ensemble. The X-axis represents the interactions ordered by their frequencies, f(|w<sub>ij</sub>| &gt; 0.2). The part of the long tail, which corresponds to the edges with frequencies less than 0.05, is not displayed. A set of well reported interactions such as the coupling of AKT activity node to phospho-AKT and phospho-MEK to phosho-MAPK (ERK) are inferred with |w<sub>ij</sub>| &gt; 0.2 in &gt;99% of the model solutions (left). Few examples of the rarely captured signaling interactions are given on right. Bottom: the frequency distribution of nonzero edges (|w<sub>ij</sub>| &gt; 0.2) has a bimodal character. A set of interactions with nonzero edge values is shared by nearly all of the inferred network models (0.8 &lt; f(|w<sub>ij</sub>| &gt; 0.2) &lt; 1.0). Such frequent edges form a stable network skeleton shared by majority of the solutions. On the other hand, a set of possible interactions have nonzero edge strength (w<sub>ij</sub>) values in ∼50% of the solutions. Such interactions vary among different model solutions and possibly account for the variations in system response predicted with different model solutions. The interactions in the prior model are particularly enriched in these two groups. A large fraction of potential interactions have very low (0.05 &lt; f(|w<sub>ij</sub>| &gt; 0.2) &lt; 0.20) or near zero (f(|w<sub>ij</sub>| &gt; 0.2) &lt; 0.05) frequencies in the model ensemble.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.017">http://dx.doi.org/10.7554/eLife.04640.017</ext-link></p></caption><graphic xlink:href="elife-04640-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.018</object-id><label>Figure 4—figure supplement 3.</label><caption><title>Comparison of random and actual prior information.</title><p>We tested whether the database driven prior model conforms to the experimental data and prior information does not overly restrain the inferred models. For this purpose, we constructed and compared network models using the pathway driven and randomly generated prior restraints in BP-based modeling. We have tested 500 unique, randomly generated pseudoprior restraints each containing 154 interactions, equal to the number of interactions in the pathway driven prior model. The models are generated using a fast BP-based inference method, which is different than the BP-based decimation. For model construction, we first computed the probability distribution of edge values (P(W<sub>ij</sub>)) for each possible interaction. Next, we constructed the models by assigning the edge value (W<sub>ij</sub>) for which BP-generated P(W<sub>ij</sub>) is maximum. We compared the models generated with different prior models for their prior scores (i.e., number of edges, which were both accepted by the algorithm and included in the prior model). The models generated using the database driven priors had significantly higher accepted priors compared to the randomly generated models (p &lt; 0.05 Student's <italic>t</italic>-test for H0: μ<sub>ps</sub><sup>random</sup> = μ<sub>ps</sub><sup>database-driven</sup>). Note that, we performed 500 parallel BP runs using identical, database driven prior models. We observed a low degree of variation in the number of accepted priors when the models are generated using the database driven priors. This is indicative of some solution degeneracy in the models. In predictive network modeling, we accounted for the solution degeneracy by re-computing the P(W<sub>ij</sub>) at the initial step of each BP-guided decimation calculation.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.018">http://dx.doi.org/10.7554/eLife.04640.018</ext-link></p></caption><graphic xlink:href="elife-04640-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.019</object-id><label>Figure 4—figure supplement 4.</label><caption><title>A subset of the prior information is represented in the average network model.</title><p>The average model, which was generated from the solutions inferred with the BP-guided decimation algorithm, contains 202 interactions in total and 89 of these interactions (blue edges) are also sampled in the qualitative prior model, which contains 154 interactions. 65 prior edges are not represented in the average model as the prior bias in network inference did not conform to the experimental data and not accepted frequently in the model ensemble. Note that a majority of the interactions in the prior set is sampled by only a fraction of the models; however, those interactions are not sufficiently strong and/or frequent that they are not captured in the average model (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.019">http://dx.doi.org/10.7554/eLife.04640.019</ext-link></p></caption><graphic xlink:href="elife-04640-fig4-figsupp4-v1.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.020</object-id><label>Figure 4—figure supplement 5.</label><caption><title>Optimization of network inference cost function parameters.</title><p>We performed an error and connectivity analysis of BP-generated models with varying cost function parameters (sum-of-squares error [SSE]: β, model complexity: λ, prior information: κ). The network models are generated using the SkMel-133 proteomic/phenotypic response data and the BP-based inference method as in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>. The SSE and model complexity (number of edges in the model) are calculated for each inferred model. We searched for the inference parameters that lead to low SSE and an intermediate model complexity (e.g., 1.5 &lt; [(#edges)/(#nodes)] &lt; 2.0). (<bold>A</bold>) The β and λ is incremented systematically while κ = λ. A low SSE with a desired connectivity level is reached for β = 2, λ = 5 and κ = 5. For different parameter sets, we obtained lower errors only for extremely connected networks inferred with high β values and so with a high weight on error in BP-optimization (e.g., β = 5, λ = 5, κ = 5, SSE = 3.8, #edges = 252). (<bold>B</bold>) The β and λ is incremented while κ is fixed (κ = 5) to determine the optimum solution with better SSE and connectivity level for (κ = 5). The parameter set, β = 2 and λ = 5 yielded the most desired SSE and connectivity values. (<bold>C</bold>) The κ is incremented for fixed β and λ (β = 2, λ = 5). The error is relatively insensitive to variations in κ as the final error is in the range of 5.6–6.1 for different κ values, although the connectivity increases with increasing prior strength in the cost function. This suggests that the error is mainly driven by the global β and λ terms at least around the tested β and λ values. Increasing κ, which is nonzero for only a small fraction (&lt;2%) of possible interactions in the model, may enforce an increase in number of nonzero edges with an incremental effect on the error. κ = 5 yielded a desired connectivity value with a sufficiently low SSE. We used the parameter set (β = 2, λ = 5, κ = 5) in all BP-guided decimation calculations with the SkMel-133 data.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.020">http://dx.doi.org/10.7554/eLife.04640.020</ext-link></p></caption><graphic xlink:href="elife-04640-fig4-figsupp5-v1.tif"/></fig></fig-group></p></sec><sec id="s2-4-2"><title>Global analysis of average models</title><p>The average network model provides a detailed overview of the signaling events in melanoma cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The average model contains 202 unique interactions (127 activating and 75 inhibitory interactions) between 99 signaling entities. 89 of the 154 interactions in the prior model conform to the experimental data, and therefore, are accepted in the majority of the model solutions by the inference algorithm and included in the average model (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). Given that the average model covers interactions from multiple signaling pathways and is more complex than the pathway diagrams presented in most review papers, even the qualitative analysis of the model is highly challenging.</p></sec><sec id="s2-4-3"><title>Network models capture known signaling pathways</title><p>In order to simplify the analysis of the average model solution, we fragmented the global network diagram into subnetworks (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Each subnetwork is a simplified representation of the signaling events in canonical pathways such as those that fall into ERK, PI3K/AKT, and cell cycle pathways (<xref ref-type="fig" rid="fig4">Figure 4C–E</xref>). The subnetwork diagrams indicate that models recapitulate many known interactions in pathways, which are important in melanoma tumorigenesis (e.g., PI3K/AKT and ERK) and nominate previously unidentified interactions (see <xref ref-type="fig" rid="fig4">Figure 4</xref> legend). It is, however, not possible to predict the cellular response to untested drug perturbations through qualitative analysis of the inferred interactions. We use quantitative simulations with in silico perturbations to both decode the signaling mechanisms and more importantly systematically predict cellular response to combinatorial drug perturbations.</p></sec></sec><sec id="s2-5"><title>Combinatorial in silico perturbations generate an expanded proteomic/phenotypic response map</title><sec id="s2-5-1"><title>Model execution with in silico perturbations</title><p>Thanks to their ordinary differential equation (ODE)-based mathematical descriptions, the models can be executed to predict cellular responses to novel perturbations (<xref ref-type="bibr" rid="bib42">Nelander et al., 2008</xref>). The systematic predictions from the models go beyond the analysis of few particular edges in the system and capture the collective signaling mechanisms of response to drugs. We execute the parameterized model ODEs (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>) with in silico perturbations acting on node (i) as a real numbered u(i) value until all the system variables (i.e., node values, {x<sub>i</sub>}) reach to steady state (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>).<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.005</object-id><label>Figure 5.</label><caption><title>Simulations with in silico perturbations provide predictions on system response to novel perturbations.</title><p>(<bold>A</bold>) The schematic description of network simulations. The system response to paired perturbations is predicted by executing the ODE-based network models with in silico perturbations. In the ODE-based models, {W<sub>ij</sub>} represents the set of interaction strengths and is inferred with the BP-based modeling strategy. The in silico perturbations are applied as real-valued u<sub>i</sub><sup>m</sup> vectors. The time derivative and final concentration of any predicted node is a function of the model parameters, the perturbations, and the values of all the direct and indirect upstream nodes in the models. (<bold>B</bold>) The model equations are executed until all model variables (protein and phenotype responses) reach to steady state. The predicted response values are the averages of simulated values at steady state over 4000 distinct model solutions. (<bold>C</bold>) The simulations expand the response map by three orders of magnitude and generate testable hypotheses. (<bold>D</bold>–<bold>H</bold>) The predicted phenotypic response to combinatorial in silico perturbations. Each box contains the 100 highest phenotypic responses to paired perturbations. The first box includes the response predictions for combined perturbations on primary targets (e.g., aMEK, c-Myc for G1-arrest. Also see <xref ref-type="table" rid="tbl1">Table 1</xref> for the definition of the term ‘primary target’). The second to sixth boxes include the predicted response for combined targeting of the primary targets with all other nodes (Nx). The last box represents the predicted response data for combination of all nodes except the primaries. For the complete predicted phenotypic response see <xref ref-type="fig" rid="fig5s1 fig5s2">Figure 5—figure supplements 1, 2</xref>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.005">http://dx.doi.org/10.7554/eLife.04640.005</ext-link></p></caption><graphic xlink:href="elife-04640-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.006</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Prediction of phenotypic responses to in silico combinatorial perturbations.</title><p>We computationally predicted cell viability and cell cycle arrest (G1, S, G2, and G2M) in response to combinatorial perturbations on all proteomic nodes in the network models (see <xref ref-type="table" rid="tbl1">Table 1</xref> and <xref ref-type="fig" rid="fig5 fig6">Figures 5, 6</xref>). In silico perturbations include paired combinations of 94 perturbations in four different perturbation strengths (equivalent to IC0-20-40-60-80 with respect to the basal level of a particular node) leading to more than 70,000 unique perturbation conditions. Each in silico perturbation is applied to 4000 inferred network models. This leads to a simulation of ∼28 million unique conditions for 99 different readouts and nearly a 2.8 billion total predicted readouts over all models, a scale inaccessible by most experimental screening methods. The heatmaps display the phenotypic response landscape to combinatorial perturbations. Each data point on the heatmaps is the response to a perturbation averaged over predictions from 4000 network models. (<bold>A</bold>) Cell viability response to combinatorial perturbations. The desired response from a perturbation is reduction in cell viability (red: decreased cell viability, green: increased cell viability). (<bold>B</bold>–<bold>E</bold>) Same as in <bold>A</bold> but for cell cycle progression phenotypes. For cell cycle phenotypes, the desired response is an increase in the cell cycle arrest (red: increased cell cycle arrest. green: decreased cell cycle arrest).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.006">http://dx.doi.org/10.7554/eLife.04640.006</ext-link></p></caption><graphic xlink:href="elife-04640-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.007</object-id><label>Figure 5—figure supplement 2.</label><caption><title>The top ten most effective single-agent in silico perturbations for each phenotype.</title><p>The listed proteomic entities for each phenotype are potential drug targets for slowing down the growth of melanoma cells. The error bars represent the ±SEM over the simulations of all model solutions.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.007">http://dx.doi.org/10.7554/eLife.04640.007</ext-link></p></caption><graphic xlink:href="elife-04640-fig5-figsupp2-v1.tif"/></fig></fig-group></p></sec><sec id="s2-5-2"><title>Prediction of phenotypic responses</title><p>The simulations expand the size of the response map by three orders of magnitude (i.e., from few thousand experimental response data to millions of predicted responses) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Once we had the predicted response profiles, we searched for specific perturbations that may induce desired phenotypic changes even when cells are treated with drugs at physiologically relevant doses. For this purpose, we identified the top ranked perturbation conditions in terms of their predicted influence on each phenotype and nominated them for further experimental testing (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1F</xref>). Not surprisingly, the execution of models quantitatively recaptured the experimentally observed associations between the drug perturbations and the phenotypic responses. For example, targeting PKC or CDK4 with specific kinase inhibitors lead to reduction of cell viability according to the simulations, which can also be directly observed from the experiments. However, CDK4 and PKC inhibitors substantially reduced SkMel-133 cell viability only at high doses, as in the original perturbation experiments (&gt;2 μM) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). More importantly, the simulations allowed us to identify effective perturbation combinations that cannot be trivially deduced from the experimental data (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="fig" rid="fig5">Figure 5D–H</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1F</xref>).<table-wrap id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.021</object-id><label>Table 1.</label><caption><p>Phenotypic nodes and predicted responses from simulations with in silico perturbations</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.021">http://dx.doi.org/10.7554/eLife.04640.021</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Phenotype</th><th>Immediate upstream nodes (&lt;w<sub>ij</sub>&gt; in average model)</th><th>Predicted primary target<xref ref-type="table-fn" rid="tblfn1"><sup>*</sup></xref></th><th>Predicted combination partners</th></tr></thead><tbody><tr><td rowspan="2">Cell viability</td><td>SMAD3 (0.49)</td><td>aPKC</td><td rowspan="2">SMAD3, 4EBP1pT70, TSC2, MAPK14/p38</td></tr><tr><td>cyclin E1 (−0.28)</td><td>aCDK4</td></tr><tr><td rowspan="2">G1-arrest</td><td>p27/KIP1 (0.83)</td><td>c-Myc</td><td rowspan="2">Cell cycle (cyclin B1, RBpS807, cyclin D1, PLK1), MAPK pathway (MAPKpT202, MEKpS217, BRAF, aBRAF), AKT, AKTpT308, RAD51, p38/MAPK14, aSRC, YBIpS102, cJUNpS73, SMAD3</td></tr><tr><td>PDK1pS241 (0.20)</td><td>aMEK</td></tr><tr><td>G2-arrest</td><td>aHDAC (−0.77)</td><td>aHDAC</td><td>Generic response from all nodes</td></tr><tr><td rowspan="4">S-arrest</td><td>STAT3pY705 (−0.66)</td><td rowspan="2">aCDK4</td><td rowspan="2">aPKC, SMAD3pS423, STAT3pS705, IGFBP2, cyclin B1, IGF1Rβ, Fibronectin</td></tr><tr><td>IGF1Rβ (−0.20)</td></tr><tr><td>SMAD3pS423 (−0.23)</td><td rowspan="2">aPKC</td><td rowspan="2">STAT3pS705</td></tr><tr><td>aCDK4 (−0.49)</td></tr><tr><td rowspan="2">G2M</td><td>aJAK (−0.24)</td><td rowspan="2">aMDM2</td><td rowspan="2">aJAK, aSTAT3, BRAF, 4EBPpT70</td></tr><tr><td>aMDM2 (−0.38)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>*</label><p>A proteomic node is a primary target when substantial phenotypic change is predicted in response to perturbation of the node alone. The phenotypic response is further increased when the primary targets are perturbed in combination with a set of other nodes (i.e., the combination partners). Also See <xref ref-type="fig" rid="fig5">Figure 5D–H</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1D</xref> and <xref ref-type="fig" rid="fig5s1 fig5s2">Figure 5—figure supplements 1, 2</xref>.</p></fn></table-wrap-foot></table-wrap></p><p>The execution of the models identified a set of perturbation conditions that are likely to induce a strong phenotypic response. The listed predicted targets (<xref ref-type="table" rid="tbl1">Table 1</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1F</xref>) will serve as a useful resource to nominate intervention strategies to overcome RAFi resistance in melanoma. In particular, in silico perturbations of c-Myc lead to the strongest G1-arrest response when c-Myc is co-targeted with BRAF, MEK, and cyclin D1 (<xref ref-type="fig" rid="fig5 fig6">Figures 5D–H, 6A</xref>). The G1-arrest phenotype is of particular interest given that induction of G1-arrest is a promising strategy for controlling melanoma growth (<xref ref-type="bibr" rid="bib58">Solit et al., 2006</xref>) and various genomic alterations associated with G1/S transition are involved in tumor progression (<xref ref-type="bibr" rid="bib51">Rother and Jones, 2009</xref>). Consistent with the vast literature on c-Myc's role in genesis of many cancers (<xref ref-type="bibr" rid="bib12">Dang, 2012</xref>), predictions indicated that c-Myc linked multiple pathways such as ERK and PI3K/AKT to regulation of cell cycle arrest (<xref ref-type="table" rid="tbl1">Table 1</xref>; also see <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref> for the highly complex c-Myc response to targeted perturbations in the underlying RPPA data). As neither c-Myc nor its direct regulators were inhibited in the perturbation experiments, the predictions from the models were nontrivial and we decided to test these predictions experimentally.<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.022</object-id><label>Figure 6.</label><caption><title>The combined targeting of c-Myc with MEK and BRAF leads to synergistic response in melanoma cells.</title><p>(<bold>A</bold>) The isobolograms of predicted G1-response to combined targeting of c-Myc with MEK, BRAF, cyclin D1, and pJUNpS73. The leftward shift of isocurves implies synergistic interactions between the applied perturbations particularly for co-targeting of c-Myc with MEK or BRAF. <bold>u</bold> denotes strength of in silico perturbations. (<bold>B</bold>) RAFi inhibits MEK phosphorylation at S217 and MEKi inhibits ERK phosphorylation at T202 in a dose-dependent manner (first 2 gels). Western blot shows the level of c-Myc in response to JQ1, MEKi, RAFi, and their combinations (24 hr) (third gel). c-Myc expression is targeted with JQ1 combined with MEKi or RAFi. Direct target of JQ1, BRD4 protein is expressed in both control and 500 nM JQ1-treated cells (fourth gel) (See <xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4</xref> for uncropped western blot images). (<bold>C</bold>, <bold>D</bold>) The cell cycle progression phenotype in response to JQ1 and RAFi as measured using flow cytometry. 46% and 51% of cells are in G1-stage 24 hr after RAFi and JQ1 treatment, respectively. The combination has a synergistic effect on G1 cell cycle arrest (G1 = 84%). 39% of cells are in G1 when they are not treated with drugs. On panel <bold>D</bold>, error bars in right panel: ±SE in three biological replicates <bold>E</bold>. The drug dose–response curves of cell viability for MEKi + JQ1 (top) and RAFi + JQ1 (bottom). Cell viability is measured using the resazurin assay. Error bars: ±SEM in three biological replicates <bold>F</bold>. The synergistic interactions between JQ1 and RAFi/MEKi. 1 − A<sub>max</sub> is the fraction of cells alive in response to highest drug dose normalized with respect to the nondrug treated condition (top panel). Combination index (CI) quantifies the synergistic interactions between drugs (bottom left). CI is calculated at a given level of inhibition and is a measure of the fractional shift between the combination doses (C1 and C2) and the single agent's inhibitory concentration (C<sub>x,1</sub>, C<sub>x,2</sub>).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.022">http://dx.doi.org/10.7554/eLife.04640.022</ext-link></p></caption><graphic xlink:href="elife-04640-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.023</object-id><label>Figure 6—figure supplement 1.</label><caption><title>The cell viability response to CDK4i and PKCi.</title><p>The IC50 for CDK4i is ∼2 μM in SkMel-133 cells. The maximum response is reached at ∼10 μM. The IC50 for CDK4i is ∼1 μM and maximum response is reached at 4 μM in SkMel-133 cells. CDK4i (2μ) and PKCi (3.5–7 μM) were used in original input perturbation data. The models recapitulated the effect of high doses of PKC and CDK4 inhibitors required to decrease cell viability. However, no significant effect on viability is observed in the biologically more relevant nM range.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.023">http://dx.doi.org/10.7554/eLife.04640.023</ext-link></p></caption><graphic xlink:href="elife-04640-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.024</object-id><label>Figure 6—figure supplement 2.</label><caption><title>Changes in c-Myc level in response to perturbations in SkMel-133 cells as measured with RPPA experiments.</title><p>Each data point is log normalized with respect to the c-Myc level in unperturbed condition. c-Myc level is highest when cells are treated with CDK4i. Various drug combinations that include STAT3 and mTOR inhibitors follow CDK4i combinations. c-Myc level is lowest when cells are perturbed with MEK, BRAF, SRC, PKC, and HDAC inhibitors, respectively. Each data point is the average of RPPA readouts from three replicates.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.024">http://dx.doi.org/10.7554/eLife.04640.024</ext-link></p></caption><graphic xlink:href="elife-04640-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.025</object-id><label>Figure 6—figure supplement 3.</label><caption><title>Cell cycle arrest response of melanoma cells to JQ1 and MEKi combination.</title><p>51% and 88% of cells are in G1-stage 24 hr after JQ1 and MEKi treatment, respectively. JQ1 + MEKi combination has an increased effect on G1 cell cycle arrest (G1 = 92%). 39% of cells are in G1 when they are not treated with drugs. Error bars in right panel: ±SE in three biological replicates.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.025">http://dx.doi.org/10.7554/eLife.04640.025</ext-link></p></caption><graphic xlink:href="elife-04640-fig6-figsupp3-v1.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04640.026</object-id><label>Figure 6—figure supplement 4.</label><caption><title>Uncropped versions of the gels presented in <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title><p>In the fourth gel, the observed band at ∼100 kDa is most likely the BRD4 B or C isoform.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.026">http://dx.doi.org/10.7554/eLife.04640.026</ext-link></p></caption><graphic xlink:href="elife-04640-fig6-figsupp4-v1.tif"/></fig></fig-group></p></sec></sec><sec id="s2-6"><title>Co-targeting c-Myc with MEK or RAF is synergistic in melanoma cells</title><p>We predicted through quantitative simulations that melanoma cells were arrested in G1-phase of the cell cycle when c-Myc was targeted alone or in combination with other proteins, particularly BRAF, MEK, and cyclin D1 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We experimentally tested the key prediction from the network models. In order to target c-Myc expression, we treated melanoma cells with the BET bromodomain inhibitor, JQ1, as a single agent and in combination with MEKi (PD-0325901) or RAFi (vemurafenib). JQ1 directly targets bromodomains, especially those of the bromodomain protein BRD4, which marks select genes including <italic>MYC</italic> on mitotic chromatin. Inhibition of the BRD4 bromodomains with JQ1 downregulates <italic>MYC</italic> mRNA transcription and leads to G1 cell cycle arrest in diverse tumor types, such as multiple myeloma (<xref ref-type="bibr" rid="bib15">Delmore et al., 2011</xref>; <xref ref-type="bibr" rid="bib34">Loven et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Puissant et al., 2013</xref>).</p><p>First, we asked whether we could affect c-Myc levels in SkMel-133 cells using JQ1. As measured by Western blot experiments, c-Myc protein expression is reduced in response to JQ1 alone. c-Myc protein levels are further reduced when the cells are treated with a combination of JQ1 and MEKi or RAFi (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p><p>To directly test the key prediction from the perturbation biology models, we measured the cell cycle progression response of melanoma cells to JQ1 in combination with the RAF and MEK inhibitors. We observed a strong synergistic interaction between JQ1 and RAFi (<xref ref-type="fig" rid="fig6">Figure 6C,D</xref>). 51% and 46% of melanoma cells are in G1-stage 24 hr after treatment with JQ1 (500 nM) and RAFi (200 nM), respectively, while 39% of cells are in G1-stage in the absence of any drug. On the other hand, when cells are treated with the combination of JQ1 and RAFi, a drastic increase in the fraction of cells arrested in G1-stage (84%) is observed. The single agent MEKi (50 nM) induces a strong G1-arrest phenotype in SkMel-133 cells (88% G1-stage in MEKi-treated cells vs 39% in nondrug treated cells). The combination of MEKi with JQ1 arrests an even higher fraction of the cells (92%) in the G1-stage (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>).</p><p>Before assessing the effect of JQ1-MEKi/RAFi combination on viability of melanoma cells (SkMel-133), we tested the effect of single agent JQ1 and found that the melanoma cells were considerably sensitive to single agent JQ1 treatment (cell viability IC50 = 200 nM). The sensitivity of SkMel-133 to JQ1 is similar to those of A375 and SkMel-5 lines (RAFi/MEKi sensitive, carrying <italic>BRAFV600E</italic> mutation) to another BRD4 inhibitor, MS417 (<xref ref-type="bibr" rid="bib56">Segura et al., 2013</xref>). The observed sensitivity is also comparable to those of multiple myeloma and MYCN-amplified neuroblastoma cell lines, reported to be potentially JQ1-sensitive tumor types (<xref ref-type="bibr" rid="bib15">Delmore et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Puissant et al., 2013</xref>), and substantially higher than those of lung adenocarcinoma and MYCN-WT neuroblastoma cell lines (<xref ref-type="bibr" rid="bib32">Lockwood et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Puissant et al., 2013</xref>).</p><p>We tested the effect of combined targeting of c-Myc with MEK or BRAF on cell viability in SkMel-133 cells (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Strikingly, when combined with JQ1 (120 nM), cell viability is reduced by 50% with 120 nM of RAFi (PLX4032), whereas the IC50 for single agent RAFi is &gt;1 μM in RAFi-resistant SkMel-133 cells. Similarly, when combined with 5 nM MEKi (PD901), viability of SkMel-133 cells is reduced by 50% with 100 nM of JQ1, an IC50 value, which is close to those of the most sensitive multiple myeloma cell lines (<xref ref-type="bibr" rid="bib15">Delmore et al., 2011</xref>). At higher doses (IC80), JQ1 is synergistic with both MEKi (combination index, CI<sub>85</sub> = 0.46) and RAFi (CI<sub>85</sub> = 0.47) in SkMel-133 cells. At intermediate doses, JQ1 synergizes with RAFi (CI<sub>50</sub> = 0.65) and has near additive interaction with the MEKi (CI<sub>50</sub> = 0.85) (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Consistent with the observed synergy at high doses, both JQ1 combinations significantly improve the maximal effect level (A<sub>max</sub>, response to the drugs at highest doses), leading to lower cell viability beyond the levels reached by treatment with any of the agents alone. The observed improvement in A<sub>max</sub> is particularly important since a subpopulation of cancer cells usually resist treatment even at highest possible drug doses. Treatments with drug combinations, such as those tested here will overcome or delay emergence of drug resistance if they can shrink the size of this resistant subpopulation (i.e., lead to improved A<sub>max</sub>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We performed a series of systematic perturbation experiments and, measured proteomic and phenotypic responses in each perturbation condition. Using the high-throughput response profiles, we generated network models of signaling in melanoma cells to systematically predict cellular responses to untested drug perturbations. Our modeling algorithm integrates high-throughput drug response profiles and pathway information from signaling databases. The scale and the predictive power of the models were beyond the reach of the previously available network modeling methods, and we made substantial progress in the design of experiments, acquisition of large profiling data sets, and improving a very efficient probabilistic network inference method. Based on the predictions from the data-driven network models, we found that co-targeting MEK or BRAF with c-Myc leads to synergistic responses that render a melanoma cell line more sensitive to inhibition of BRAF. Beyond nomination of effective drug combinations in cell lines, we suggest that the perturbation biology method more generally paves the way for model-driven quantitative cell biology with diverse applications in many fields of biology.</p><p>The problem of insensitivity or resistance to targeted therapy is both important and complicated. Oncogenic alterations that affect sensitivity to targeted therapies may pre-exist in the tumor before treatment or emerge sequentially as the result of treatment. Tumors can escape drug treatment through diverse routes and dominant mechanisms of resistance are the exception (such as the T790M mutation in EGFR, which confers resistance to EGFR inhibitors in many patients as well as in the laboratory [<xref ref-type="bibr" rid="bib46">Pao et al., 2005</xref>]), so the identification of effective countermeasures is in general difficult. Typically researchers have identified mechanisms of resistance in individual cases and proposed countermeasures based on the particular mechanism. For example, PTEN loss was associated with resistance to RAFi (in BRAFV600E mutated melanoma) and as a result joint inhibition of BRAF and PI3K was proposed as a combination therapy (<xref ref-type="bibr" rid="bib64">Villanueva et al., 2010</xref>; <xref ref-type="bibr" rid="bib67">Xing et al., 2012</xref>). Based on similar logic, other plausible therapeutic combinations that target particular escape routes in RAFi-resistant melanomas have been put forward, including combinations that target downstream elements of the ERK pathway (e.g., RAFi + MEKi) (<xref ref-type="bibr" rid="bib31">Lito, Pratilas et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Flaherty et al., 2012a</xref>), or upstream receptor tyrosine kinases (<xref ref-type="bibr" rid="bib48">Prahallad et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Sun et al., 2014</xref>). For almost all cases, however, tumor cells rapidly adapt and escape through alternate routes after a brief period of response to the combination. Even the FDA-approved RAFi + MEKi combination has only achieved limited improvements in the median progression-free survival in BRAFV600E mutated melanoma patients compared to single agent RAFi treatment (<xref ref-type="bibr" rid="bib33">Long et al., 2014</xref>). A general solution for resistance to the RAFi in BRAF-mutated melanoma, in particular, is not yet in sight.</p><p>Aiming to develop a more general strategy for preventing the emergence of drug resistance, we have taken a more systematic approach to the discovery of effective combination therapy and cast a wider net by perturbing cancer cells with an entire set of targeted inhibitors and combinations of inhibitors and observing the proteomic signaling response using hundreds of antibodies covering diverse pathways. We expected to generate plausible predictions for a set of effective combinations and to be able to rank their relative importance, to guide validation experiments. The perturbation biology approach used here identified a highly ranked co-target of RAF, downstream of the ERK pathway, the oncogene c-Myc. To test our predictions, we targeted c-Myc using the epigenetic drug JQ1, a BRD4 inhibitor that negatively affects c-Myc transcription (<xref ref-type="bibr" rid="bib15">Delmore et al., 2011</xref>). We treated SkMel-133 cells with combinations of JQ1 and MEKi or RAFi and showed that both combinations synergistically induced G1-arrest and decreased cell viability.</p><p>A key criterion of pharmacological efficacy is the ability of a drug to induce cellular responses at doses sufficient to inhibit its immediate molecular targets. In SkMel-133 cells, however, the cell viability IC50s for RAFi and MEKi are at least one order of magnitude higher than the doses required to reduce the phosphorylation of immediate downstream targets (phospho-MEK and phospho-ERK) by 50% (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, <xref ref-type="table" rid="tbl2">Table 2</xref>), and hence, the cells are considered to be relatively resistant to both drugs. When combined with JQ1, the concentrations of RAFi/MEKi that are sufficient to reduce cell viability by 50% are in the range of MEK and ERK phosphorylation IC50s (<xref ref-type="table" rid="tbl2">Table 2</xref>). This is a direct result of the strong and synergistic increase in G1-arrest phenotype in response to the drug combinations (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Thus, the JQ1-MEKi/RAFi combinations shift the required doses to induce phenotypic responses close to the doses required for inhibition of the ERK pathway activity. Interestingly, in an independent study in hematopoietic cancer, the combination of JQ1 affecting the c-Myc levels and a FLT3 tyrosine kinase inhibitor (TKI) was synergistic in overcoming resistance to the FLT3 TKI in acute myeloid leukemia (AML) cells (<xref ref-type="bibr" rid="bib19a">Fiskus et al., 2014</xref>). As far as we know, our study is the first demonstration of a combined inhibition of a BET bromodomain (BET-BRD) protein and a protein kinase molecule to overcome drug resistance in solid tumors (<xref ref-type="bibr" rid="bib19">Filippakopoulos and Knapp, 2014</xref>).<table-wrap id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.027</object-id><label>Table 2.</label><caption><p>Drug resistance is overcome as the IC50 (cell viability) approaches the IC50 (target phosphorylation)</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.027">http://dx.doi.org/10.7554/eLife.04640.027</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>JQ1</th><th>MEKi</th><th>RAFi</th></tr></thead><tbody><tr><td>IC50 (target phosphorylation)</td><td>–</td><td>3 nM<xref ref-type="table-fn" rid="tblfn2">*</xref></td><td>65 nM<xref ref-type="table-fn" rid="tblfn2">*</xref></td></tr><tr><td>IC50 (cell viability) single agent</td><td>200 nM</td><td>15 nM</td><td>&gt;1 μM</td></tr><tr><td>IC50 (cell viability) combined with JQ1</td><td>–</td><td>5 nM<xref ref-type="table-fn" rid="tblfn3">†</xref></td><td>120 nM<xref ref-type="table-fn" rid="tblfn3">†</xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>*</label><p>MEKi targets pERK and RAFi targets pMEK. Phopho-IC50s are quantified from gels (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p></fn><fn id="tblfn3"><label>†</label><p>IC50s for viability and phosphorylation are in same order.</p></fn></table-wrap-foot></table-wrap></p><p>To interpret these positive results, we note that c-Myc is a multifunctional transcription factor with a central role in cell cycle progression and receives inputs from diverse signaling pathways, including ERK, PI3K/AKT, Wnt, and TGF-β signaling (<xref ref-type="bibr" rid="bib12">Dang, 2012</xref>). We hypothesize that, beyond the efficacy of co-targeting BRAF kinase and c-Myc, there may be a particular advantage in blocking proliferative signals from various oncogenic pathways that converge on the downstream effector c-Myc. In other words, c-Myc may be a particular ‘point of vulnerability’ in RAFi drug-resistant cells (<xref ref-type="fig" rid="fig7">Figure 7</xref>) and this may be reflected in the high rank of c-Myc as a co-target to induce G1-arrest phenotype in the data-driven perturbation biology network models.<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.04640.028</object-id><label>Figure 7.</label><caption><title>Upstream–downstream combination therapy.</title><p>Co-targeting a specific genomic upstream alteration (here, a BRAFV600E mutant) and a general downstream point of vulnerability (here, c-Myc) may be an effective strategy to overcome drug resistance, as it has the potential dual advantage of specificity and generality. The specificity of targeting an upstream oncogenic activator such as BRAFV600E reduces the likelihood of toxicity because normal cells depend much less or not at all on the activator. The generality of targeting a downstream signaling molecule such as c-Myc increases the likelihood of blocking diverse bypass mechanisms. Signaling pathways such as Wnt, RTK, TGFβ, and various others influence c-Myc stability, expression, and activity. For example, ERK phosphorylates c-Myc at S62 to stabilize the molecule, while phosphorylation at T58 by GSK3 leads to ubiquitylation and degradation. β-catenin and SMAD3 act as transcriptional activator and repressor of c-Myc, respectively. RAF-inhibitor resistance can, for example, be mediated by the activities of the Wnt (<xref ref-type="bibr" rid="bib1">Anastas et al., 2014</xref>), TGFβ (<xref ref-type="bibr" rid="bib61">Sun et al., 2014</xref>), or RTK (<xref ref-type="bibr" rid="bib64">Villanueva et al., 2010</xref>; <xref ref-type="bibr" rid="bib67">Xing et al., 2012</xref>) pathways.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.028">http://dx.doi.org/10.7554/eLife.04640.028</ext-link></p></caption><graphic xlink:href="elife-04640-fig7-v1.tif"/></fig></p><p>Although the experiments here are limited to the SkMel-133 melanoma cell line, we are tempted to put forward a more general hypothesis. We suggest that synergistic co-targeting of a key genomic aberration (e.g., BRAFV600E) and a downstream point of convergence of signaling (e.g., c-Myc) may be a more effective way of overcoming the resistance than co-targeting another upstream pathway (<xref ref-type="fig" rid="fig7">Figure 7</xref>). While inhibition of the oncogenic activation by the first drug can be compensated by alteration in a number of bypass pathways, it is plausible that most if not all signaling events have to converge on similar, pro-proliferative consequences—in this example via the downstream transcriptional activator c-Myc. Inhibition of a downstream signaling event may therefore be a generally more effective co-targeting strategy for an entire set of alternative upstream bypass mechanisms of resistance. The key proviso, of course, is absence of toxicity, which may be more likely for co-targeting the upstream oncogenic activator (not active in normal cells, e.g., BRAV600E) in combination with a downstream effector (functional in both normal and tumor cells, e.g., c-Myc [<xref ref-type="bibr" rid="bib60">Soucek et al., 2008</xref>]) at optimized drug concentrations. In other words, the upstream–downstream combination of targets may have the dual advantage of generality in overcoming resistance and avoidance of toxicity. To generally test this hypothesis, one would have to go beyond the scope of this work and perform co-targeting experiments in other melanoma cell lines, for which the mechanism of resistance is known, or more generally, in other cell lines or mouse models of resistance to targeted therapeutics.</p><p>In the current study, we have only tested the JQ1 and RAF-inhibitor combinations in vitro<italic>.</italic> Future in vivo studies will be important for identifying the optimal BET-BRD inhibitor for combination therapy in melanoma and other tumors. This may be clinically relevant, as BET-BRD inhibitors hold substantial clinical potential for treatment of both solid and hematological tumors. Indeed, the observation that BET-BRD inhibitors (e.g., JQ1) effectively block cellular growth through transcriptional repression of c-Myc in mouse models has created the rationale for clinical trials in c-Myc-dependent cancer types (<xref ref-type="bibr" rid="bib36">Mertz et al., 2011</xref>). Unfortunately, the widely used investigational BET-BRD inhibitor JQ1 has been reported to have poor in vivo efficacy with low metabolic stability and bio-solubility, but fortunately, other BET-BRD inhibitors with more promising pharmacokinetic properties have been and are being developed. Specifically, JQ1 is reported to have a maximum blood concentration of 0.84 μM in mouse models, whereas the compounds I-BET-762 and I-BET-151 reach maximum blood concentrations of 26 μM and 82 μM, respectively (<xref ref-type="bibr" rid="bib14">Dawson et al., 2011</xref>). In general, triazolobenzodiazepine (e.g., I-BET-762 and I-BET-151 compounds) and triazolothienodiazepine (e.g., OTX015, TEN-010, CPI-0610 compounds) BET-BRD inhibitors are reported to be stable in liver microsomes and have up to 30% bioavailability. These compounds may therefore be more suitable for in vivo applications (<xref ref-type="bibr" rid="bib19">Filippakopoulos and Knapp, 2014</xref>). Several clinical trials of BET-BRD inhibitors with desirable pharmacokinetic properties have been initiated in multiple cancer types, including trials with OTX015 for the treatment of acute leukemia (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01713582), CPI-0610 for progressive lymphoma (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01949883), I-BET-762 and TEN-010 for NUT midline carcinoma (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01587703, NCT01987362), and a dose escalation and cohort expansion study for TEN-010 in patients with AML and myelodysplastic syndrome (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT02308761). The trials with BET-BRD inhibitors in different cancer sub-types suggest use of such compounds either as single agents or in combinations may be a plausible strategy for treatment of other cancer types, including RAF-inhibitor resistant melanoma.</p><p>The model-based predictions provide comprehensive and testable hypotheses on complex signaling mechanisms relevant to the development of novel therapies. More comprehensive experimental data and improvements in signaling databases are likely to lead to network models with even higher predictive power. Interpreting the cell line-specific predictions on the background of genomic profiling of tumor samples from patients may guide therapeutic choices for tumors with similar genomic backgrounds. To assist in these efforts, we have developed genomics methods to classify tumors based on patterns of functional oncogenic alterations and to identify cell lines that most closely resemble tumors (<xref ref-type="bibr" rid="bib10">Ciriello et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Domcke, Sinha, et al., 2013</xref>). By integrating network models, genomics, and pathway analysis, one can expect to generate whole-cell models of signaling and drug response in mammalian cells with potential applications to personalized medicine and genomically informed clinical trials.</p><sec id="s3-1"><title>Website</title><p>Website for the perturbation biology method: <ext-link ext-link-type="uri" xlink:href="http://www.sanderlab.org/pertbio/">http://www.sanderlab.org/pertbio/</ext-link>. The website stores the source code for BP-decimation algorithm, input scripts, and data files for running the BP-guided decimation code, perturbation response data, downloadable files for the executable model solutions, and the complete simulation results. A detailed description of the perturbation biology method is also provided in the webpage.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Computational methods</title><sec id="s4-1-1"><title>Automated extraction of prior information from signaling databases</title><p>Pathway Extraction and Reduction Algorithm (PERA) was developed to automatically extract prior information from multiple signaling databases and generate a prior information network. The input to PERA is a list of (phospho) proteins identified by their HGNC symbols (e.g., <italic>AKT1</italic>), phosphorylation sites (e.g., pS473), and their molecular status (i.e., activating or inhibitory phosphorylation, total concentration). The output of PERA is a set of directed interactions between signaling molecules represented in a Simple Interaction Format (SIF). The PERA software is available at <ext-link ext-link-type="uri" xlink:href="http://bit.ly/bp_prior">http://bit.ly/bp_prior</ext-link> as a free software under LGPL 3.0.</p><sec id="s4-1-1-1"><title>Requirements for prior information</title><p>There is a growing number of signaling databases (<xref ref-type="bibr" rid="bib2">Bader et al., 2006</xref>) that capture pathway information in high detail. Compared to the interaction networks with relatively low level of detail, pathway databases contain information about the phosphorylation states of proteins and interactions specific to these states. Although this corpus is highly valuable for phospho-proteomic analysis, it remains mostly untapped. To utilize this knowledge, one needs algorithms to map the experimentally measured proteins and phosphoproteins to their pathway database equivalents, find connections between them, and reduce the outcome to a format that can be used for inference and analysis.</p></sec><sec id="s4-1-1-2"><title>The algorithm</title><p>We developed the algorithm and the software tool, PERA to automatically extract prior information from multiple signaling databases in the BioPAX (<xref ref-type="bibr" rid="bib16">Demir et al., 2010</xref>) format and generate a prior information network. PERA takes a list of (phospho)proteins identified by their HGNC symbols (e.g., AKT1), phosphorylation sites (e.g., pS473), and their molecular status (i.e., activating or inhibitory phosphorylation, total concentration) as input and then finds directed signaling paths between these entities. These paths are then reduced to directed interactions between signaling molecules represented in a SIF.</p></sec><sec id="s4-1-1-3"><title>The PERA framework</title><p>The prior information is extracted from components of the Pathway Commons 2 database in three steps: first, using the paths-between graph query algorithm (<xref ref-type="bibr" rid="bib17">Dogrusoz et al., 2009</xref>), PERA generates a sub-graph (i.e., graph-of-interest) of Pathway Commons, which contains all the input proteins and all known connections within their first neighborhoods. Second, using the phosphorylation and activity state information, input entities are mapped to the corresponding protein states in the graph-of-interest. During this mapping step, protein states that do not match with either the corresponding annotation for phosphorylation or activity state are filtered out. Phosphorylation site mismatches up to six residues are tolerated during the filtering step to account for phosphorylation site ambiguities due to either database curation errors or cross-organism annotations. Third, paths that result in the addition or removal of a phopho-group at a phosphorylation site are extracted and mapped to phosphoprotein nodes. For total protein nodes, all nonphosphoprotein specific, directed signaling paths are included. For this application, the maximum allowable graph query distance limit was set to 1 and only the Reactome (<xref ref-type="bibr" rid="bib35">Matthews et al., 2009</xref>) and NCI-Nature PID pathway (<xref ref-type="bibr" rid="bib54">Schaefer et al., 2009</xref>) data resources were used. Although we limited ourselves to short path distances and two pathway databases that we were most familiar with, PERA can be applied to extract information from any pathway database that exports to BioPAX and can be configured for searching paths of arbitrary length.</p></sec><sec id="s4-1-1-4"><title>Key considerations for extracting pathway information</title><p>Two major semantic issues need to be taken into account when extracting state-specific pathway information from databases. First semantic issue stems from the ambiguities in mapping proteins with multiple phosphorylation sites. When a protein with multiple phosphorylation sites is experimentally profiled with an antibody, which recognizes only a single phosphorylation site, the antibody will actually bind to a heterogeneous mixture of phospho-states provided that the epitope is phosphorylated (e.g., anti-AKTpS473 Ab may bind to both AKTpS473 and AKTpS473_pT308 but not to AKTpT308). For proteins with multiple observed phosphorylation sites, this might lead to semantic conflicts since a double phosphorylated node should be mapped to both observations (i.e., single and double-phosphorylated states). We included an optional ‘strict’ mapping scheme to map only the phosphoproteins that exactly match the observed node—in our case always single phosphoproteins (e.g., the epitope of anti-AKTpS473 Ab is mapped to AKTpS473 but not to AKTpS473_pT308). Since our extraction algorithm is much more tolerant of missing interactions compared to false interactions, we opted to use this flag for this application.</p><p>The second semantic issue stems from the fact that pathway databases are often curated from multiple independent studies, spanning multiple cellular states, cell and tissue types, and even multiple model organisms. As a result, they are a superimposition of possible interactions over a wide range of spatiotemporal and genetic contexts. On the other hand, databases cover only a subset of all possible contexts. In our case, we expect only a subset of the interactions in the pathway databases to be active in our cell lines and cover only a subset of the interactions that we observe. This observation necessitates incorporating prior information as ‘soft’ restraints for network inference. For this purpose, we devised a modified cost function, which includes a term for prior information (See below. Also see [<xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al., 2013</xref>] and [<xref ref-type="bibr" rid="bib37">Miller et al., 2013</xref>]).</p></sec></sec><sec id="s4-1-2"><title>Mathematical description of network models</title><p>The network models represent the time behavior of the cellular system in a set of perturbation conditions as a series of coupled nonlinear ODEs (<xref ref-type="bibr" rid="bib42">Nelander et al., 2008</xref>).</p><sec id="s4-1-2-1"><title>Equation 1. Network model ODEs</title><p><disp-formula id="equ1"><label>(1a)</label><mml:math id="m1"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mi>ϕ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mi>j</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:msubsup><mml:mi>u</mml:mi><mml:mi>i</mml:mi><mml:mi>μ</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ2"><label>(1b)</label><mml:math id="m2"><mml:mrow><mml:mi>ϕ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>z</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext>tanh</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>z</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>In the network models, each node represents the quantitative change of a biological variable, <italic>x</italic><sup><italic>μ</italic></sup><sub><italic>i</italic></sub> ((phospho)protein level and phenotypic change) in the perturbed condition, <italic>μ</italic>, relative to the unperturbed condition. <italic>W</italic><sub><italic>ij</italic></sub> quantifies the edge strength, which is the impact of upstream node j on the time derivative of downstream node i. We assign semi-discrete values to each <italic>W</italic><sub><italic>ij</italic></sub>, <bold><italic>W</italic></bold> = {<italic>w</italic><sub><italic>ij</italic></sub><italic>,</italic> ∀<italic>w</italic><sub><italic>ij</italic></sub> ∈ {−1, −0.8,…,0.8, 1}}. <italic>α</italic><sub><italic>i</italic></sub> constant is the tendency of the system to return to the initial state, and <italic>ε</italic><sub><italic>i</italic></sub> constant defines the dynamic range of each variable <italic>i</italic>. The transfer function, <italic>Φ</italic>(x) ensures that each variable has a sigmoidal temporal behavior.</p></sec></sec><sec id="s4-1-3"><title>Modified cost function for network inference with prior information</title><p>We have quantified the cost of a model solution by an objective cost function C(W). The network configurations with low cost represent the experimental data more accurately. Here, we have incorporated an additional prior information term to the cost function to construct models with improved predictive power. The newly introduced term in the cost function accounts for the prize introduced when the inferred w<sub>ij</sub> is consistent with the prior information.</p><p>In order to generate predictive network models of signaling, we have quantified the cost function C(W) to penalize (a) discrepancies between predicted (x<sub>i</sub><sup>μ</sup>) and experimental (x<sub>i</sub><sup>μ*</sup>) values of the system variables at a time point {t<sub>l</sub>} in condition μ, and (b) the number of nonzero interactions with an L0 norm (<xref ref-type="bibr" rid="bib42">Nelander et al., 2008</xref>; <xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al., 2013</xref>). Here, we have also incorporated prior information to construct network models with higher predictive power even if the models are constructed with limited experimental data. The newly introduced third term in the cost function accounts for the prize introduced when the inferred w<sub>ij</sub> conforms to the prior information (w<sub>ij</sub><sup>prior</sup>). The modified cost function with prior information term is formulated as in <xref ref-type="disp-formula" rid="equ3">Equation 2</xref>.</p><sec id="s4-1-3-1"><title>Equation 2. Modified cost function</title><p><disp-formula id="equ3"><label>(2a)</label><mml:math id="m3"><mml:mrow><mml:mi>C</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msup><mml:mi>C</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ4"><label>(2b)</label><mml:math id="m4"><mml:mrow><mml:mi>C</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mtext>W</mml:mtext><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>β</mml:mi><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>l</mml:mi><mml:mi>L</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>μ</mml:mi><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mi>δ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:math></disp-formula><disp-formula id="equ5"><label>(2c)</label><mml:math id="m5"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>δ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mtext>  </mml:mtext><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>δ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext>  </mml:mtext><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>In <xref ref-type="disp-formula" rid="equ3">Equation 2</xref>, the first term accounts for the discrepancies between predicted (<italic>x</italic><sub><italic>i</italic></sub><sup><italic>μ</italic></sup>) and experimental (<italic>x</italic><sub><italic>i</italic></sub><sup><italic>μ*</italic></sup>) values of the system variables at a time point {<italic>t</italic><sub><italic>l</italic></sub>} in condition <italic>μ</italic>, for a particular network configuration (<bold>W</bold> = {<italic>w</italic><sub><italic>ij</italic></sub>}). The second term is the complexity factor with an L0 norm, which reduces the number of nonzero interactions in a network configuration and ensures that resulting network models are sparse. The final term, η(<bold>W</bold>) is the cumulative prior prize function for <bold>W</bold> = {<italic>w</italic><sub><italic>ij</italic></sub>}. η(w<sub>ij</sub> = ω) has a negative real value and reduces the overall model cost if the inferred ω conforms to the prior information. Here, we will formulate the newly introduced prior information term in the modified cost function.</p><sec id="s4-1-3-1-1"><title>Generalized prior information prize function</title><p>In order to derive the prior information prize (PIP) function, we first assume the value of prior w<sub>ij</sub> is normally distributed (truncated by boundaries of w<sub>ij</sub>) around an expected prior value, E[w<sub>ij</sub><sup>prior</sup>] with a standard deviation, σ<sub>ij</sub><sup>prior</sup>. The prior probability model for each interaction in the prior network is formulized using the normal distribution probability density function around E[w<sub>ij</sub><sup>prior</sup>] as in <xref ref-type="disp-formula" rid="equ6">Equation 3</xref>.</p></sec></sec><sec id="s4-1-3-2"><title>Equation 3. Probability model of prior observations</title><p><disp-formula id="equ6"><label>(3)</label><mml:math id="m6"><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The <xref ref-type="disp-formula" rid="equ6">Equation 3</xref> implies that the probability of inferring a particular <italic>w</italic><sub><italic>ij</italic></sub> value and consequently, the prize introduced to the cost function increase as <italic>w</italic><sub><italic>ij</italic></sub> approaches <italic>E</italic>[<italic>w</italic><sub><italic>ij</italic></sub><sup><italic>prior</italic></sup>]. We calculate the prize for the fit between the inferred <italic>w</italic><sub><italic>ij</italic></sub> and the <italic>E</italic>[<italic>w</italic><sub><italic>ij</italic></sub><sup><italic>prior</italic></sup>] with an inverse Boltzmann conversion of the probability model (<xref ref-type="bibr" rid="bib27">Jaynes, 1957</xref>).</p></sec><sec id="s4-1-3-3"><title>Equation 4. Error model of individual prior observations</title><p><disp-formula id="equ7"><label>(4a)</label><mml:math id="m7"><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ8"><label>(4b)</label><mml:math id="m8"><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac><mml:mtext>exp</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ9"><label>(4c)</label><mml:math id="m9"><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The first term introduces the maximum possible prize for each interaction that is represented in the prior information network. Second term penalizes the discrepancies between the <italic>w</italic><sub><italic>ij</italic></sub> and the <italic>E</italic>[<italic>w</italic><sub><italic>ij</italic></sub><sup><italic>prior</italic></sup>]. The penalty for the discrepancy is zero when w<sub>ij</sub> = <italic>E</italic>[<italic>w</italic><sub><italic>ij</italic></sub><sup><italic>prior</italic></sup>] and the prior prize, <italic>η</italic>(<italic>w</italic><sub><italic>ij</italic></sub>) assumes the highest possible value. <inline-formula><mml:math id="inf1"><mml:mrow><mml:msub><mml:mi mathvariant="normal">κ</mml:mi><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">σ</mml:mi><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow><mml:mrow><mml:mtext>prior</mml:mtext></mml:mrow></mml:msubsup><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is a constant analogous to the inverse temperature in statistical physics. The constant <italic>κ</italic><sub><italic>ij</italic></sub> and the resulting <italic>η(w</italic><sub><italic>ij</italic></sub><italic>)</italic> are zero if the interaction between nodes <italic>i</italic> and <italic>j</italic> is not included in the prior network model. By summing over all <italic>i</italic> and <italic>j</italic>, the cumulative prior prize for all W = {<italic>w</italic><sub><italic>ij</italic></sub>} becomes <xref ref-type="disp-formula" rid="equ10">Equation 5</xref>.</p></sec><sec id="s4-1-3-4"><title>Equation 5. Cumulative error model of prior observations</title><p><disp-formula id="equ10"><label>(5a)</label><mml:math id="m10"><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>W</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>j</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ11"><label>(5b)</label><mml:math id="m11"><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>j</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Even though the current PIP function is derived with the normal distribution assumption, a variety of alternative distributions such as a bimodal distribution can be fitted in <xref ref-type="disp-formula" rid="equ6">Equation 3</xref>. Such efforts will lead to a variety of custom-designed PIP functions when necessary.</p><sec id="s4-1-3-4-1"><title>Estimation of E[w<sub>ij</sub><sup>prior</sup>] and σ<sub>ij</sub><sup>prior</sup></title><p>An important requirement for the implementation of <xref ref-type="disp-formula" rid="equ10">Equation 5</xref> is the accurate estimation of E[w<sub>ij</sub><sup>prior</sup>] and σ<sub>ij</sub><sup>prior</sup>. Here, we propose two estimation strategies that are alternative to systematic extraction of priors from databases.</p></sec><sec id="s4-1-3-4-2"><title>Priors from experiments</title><p>Our first strategy relies on use of biochemical measurements with multiple biological replicates to quantify the influence of node j on node i (w<sub>ij</sub>). The E(w<sub>ij</sub><sup>prior</sup>) and σ<sub>ij</sub><sup>prior</sup> can be estimated from the mean value (&lt;w<sub>ij</sub><sup>prior</sup>&gt;) and standard deviation (σ<sub>ij</sub>) of the readouts from biological replicates in such measurements. Depending on the nature of the interaction under study, a variety of different biochemical methods can be utilized. These methods include but are not limited to enzyme activity assays, quantification of protein–protein interactions (<xref ref-type="bibr" rid="bib57">Selbach and Mann, 2006</xref>), or additional RPPA readouts under specific perturbation conditions.</p></sec><sec id="s4-1-3-4-3"><title>Priors from network models</title><p>As we build network models of signaling in diverse biological contexts using perturbation data and inference algorithms, a vast amount of information on signaling properties will become available. Consequently, we will be able to estimate the E(w<sub>ij</sub><sup>prior</sup>) and σ<sub>ij</sub><sup>prior</sup> for newly inferred models from available network models. Previously inferred {w<sub>ij</sub>} values and standard deviation in BP-generated probability distributions will serve as a basis to estimate the E(w<sub>ij</sub><sup>prior</sup>) and σ<sub>ij</sub><sup>prior</sup>, respectively.</p></sec><sec id="s4-1-3-4-4"><title>The simplified PIP function</title><p>The current form of the prior information is limited to a set of binary interactions due to the qualitative nature of the databases, from which we extract the information. Therefore, we used a simplified PIP function to introduce the prior information restraints to the inference scheme. The prior information stored in the databases may correspond to activating (w<sub>ij</sub> &gt; 0), inhibitory (w<sub>ij</sub> &lt; 0), or generic (w<sub>ij</sub> ≠ 0) interactions. In such situations, w<sub>ij</sub><sup>prior</sup> has a uniform distribution within the defined boundary. Thus, the E[w<sub>ij</sub><sup>prior</sup>] can be set as equal to any value within the interval, [w<sub>ij</sub><sup>min-prior</sup>, w<sub>ij</sub><sup>max-prior</sup>]. For example, a prior for a positive interaction between nodes i and j is represented by an interval of (0, w<sub>ij</sub><sup>max</sup>), where w<sub>ij</sub><sup>max</sup> is the maximum allowed edge strength in the inference scheme. Consequently, the squared distance error in <xref ref-type="disp-formula" rid="equ7">Equation 4</xref> vanishes and the prior prize assumes a fixed value over the defined prior interval.</p></sec></sec><sec id="s4-1-3-5"><title>Equation 6. Simplified error model of prior information</title><p><disp-formula id="equ12"><label>(6a)</label><mml:math id="m12"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mtext>  </mml:mtext><mml:mo>∀</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mi>w</mml:mi><mml:mo>∈</mml:mo><mml:mi>R</mml:mi><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mtext>min</mml:mtext><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mrow><mml:mo>≤</mml:mo><mml:mi>w</mml:mi><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mtext>max</mml:mtext><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mo>∀</mml:mo><mml:mtext> i</mml:mtext><mml:mo>,</mml:mo><mml:mtext>j</mml:mtext><mml:mo>∈</mml:mo><mml:mtext>N</mml:mtext><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ13"><label>(6b)</label><mml:math id="m13"><mml:mrow><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ14"><label>(6c)</label><mml:math id="m14"><mml:mrow><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>i</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mi>j</mml:mi><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msup><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mrow></mml:msup><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The binary nature of the interactions also implies a generic κ value <inline-formula><mml:math id="inf2"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">κ=</mml:mi><mml:msub><mml:mi mathvariant="normal">κ</mml:mi><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">σ</mml:mi><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow><mml:mrow><mml:mtext>prior</mml:mtext></mml:mrow></mml:msubsup><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi></mml:mrow></mml:msqrt></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mo>,</mml:mo><mml:mtext> κ</mml:mtext></mml:mrow><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mo>∀</mml:mo><mml:mtext> i</mml:mtext><mml:mo>,</mml:mo><mml:mtext>j</mml:mtext><mml:mo>∈</mml:mo><mml:mtext>N</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> for all interactions represented in prior information network and κ = 0 for all other situations. The resulting prior information term in the cost function is a step function as shown in the main text methods section.</p></sec><sec id="s4-1-3-6"><title>Equation 7. Simplified error model of individual prior observations</title><p><disp-formula id="equ15"><label>(7)</label><mml:math id="m15"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>κ</mml:mi><mml:mtext> and </mml:mtext><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext> Generic prior information </mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mtext>w</mml:mtext><mml:mrow><mml:mtext>ij</mml:mtext></mml:mrow></mml:msub><mml:mo>≠</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>κ</mml:mi><mml:mtext> and </mml:mtext><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext> Prior information for an activating interaction </mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>κ</mml:mi><mml:mtext> and </mml:mtext><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext> Prior information for an inhibitory interaction </mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext> No Prior exists for </mml:mtext><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p>For each interaction in the prior information network, <italic>η</italic>(<italic>w</italic><sub><italic>ij</italic></sub>) has a negative value. Thus, the prior information introduces a prize in the overall cost function. The formulation and implementation into the BP equations create a soft-restraint for prior information extracted from signaling databases. In our probabilistic inference framework, a prior information is accepted as an edge (wij ≠ 0) only if the prize introduced can override any discrepancy between predicted (x<sub>i</sub><sup>μ</sup>) and experimental (x<sub>i</sub><sup>μ*</sup>) values of the system variables. Thus, the context-specific character of inferred models is preserved when the cost function in <xref ref-type="disp-formula" rid="equ3">Equation 2</xref> is used.</p></sec></sec><sec id="s4-1-4"><title>Network model construction and response prediction</title><p>Network models are constructed with a two-step strategy. The method is based on first calculating probability distributions for each possible interaction at steady state with the BP algorithm and then computing distinct solutions by sampling the probability distributions. We described the theoretical formulation, the underlying assumptions and simplification steps of the BP algorithm for inferring network models of signaling elsewhere (<xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al., 2013</xref>). The network models include 82 proteomic, 5 phenotypic, and 12 activity nodes. Activity nodes couple the effect of drug perturbations to the overall network models (See Molinelli, Korkut, Wang et al. for quantification of activity nodes).</p><sec id="s4-1-4-1"><title>Belief propagation</title><p>Belief propagation (BP) algorithm iteratively approximates the probability distributions of individual parameters. The iterative algorithm is initiated with a set of random probability distributions. In each iteration step, individual model parameters are updated (local updates) based on the approximate knowledge of other parameters, experimental constraints, and prior information (global information). In the next iteration, the updated local information becomes part of the global information and another local update is executed on a different model parameter. The successive iterations continue over different individual parameters until the updated probability distributions converge to stable distributions. The iterations between the local updates and the global information create an optimization scheme that <bold>W</bold> = {w<sub>ij</sub>} is inferred given a probability model. Explicitly, the following cavity update equations are iteratively calculated until convergence.</p></sec><sec id="s4-1-4-2"><title>Equation 8. BP update equations</title><p><disp-formula id="equ16"><label>(8a)</label><mml:math id="m16"><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mi>μ</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mi>δ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>.</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>η</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>υ</mml:mi><mml:mo>≠</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mi>M</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mi>υ</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mtext> </mml:mtext><mml:mo>∀</mml:mo><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mo>,</mml:mo></mml:mstyle><mml:mtext> </mml:mtext></mml:mrow></mml:math></disp-formula><disp-formula id="equ17"><label>(8b)</label><mml:math id="m17"><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mi>μ</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mtext> </mml:mtext><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msup></mml:mrow></mml:mstyle><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mi>P</mml:mi><mml:mi>μ</mml:mi></mml:msup></mml:mrow></mml:mstyle><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>In <xref ref-type="disp-formula" rid="equ16">Equation 8a</xref>, <italic>P</italic><sup><italic>μ</italic></sup>(<italic>w</italic><sub><italic>ij</italic></sub>) approximates the mean field of the parameters with a sparsity constraint (<italic>λδ</italic>(<italic>w</italic><sub><italic>ij</italic></sub>)) and a bias from prior information restraints (<italic>η</italic>(<italic>w</italic><sub><italic>ij</italic></sub>)). In <xref ref-type="disp-formula" rid="equ17">Equation 8b</xref>, <italic>ρ</italic><sup><italic>μ</italic></sup>(<italic>w</italic><sub><italic>ij</italic></sub> = <italic>ω</italic>) is a mean field derived change to the probability distribution of the locally optimized parameter, towards minimizing the model error (C<sup>SSE</sup>(W)). (See <xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al. (2013)</xref> for derivation and implementation of BP equations).</p><sec id="s4-1-4-2-1"><title>Gaussian integration of cavity parameter update</title><p>Information from a sufficiently large set of noncavity constraints and parameters is integrated to update the cavity parameters. As a corollary to the central limit theorem, we can assume that the mean-field effect of noncavity parameters on the cavity update follows a Gaussian distribution. The mean and variance of the Gaussian distribution are the mean values and variances of the global distributions given by individual distributions of noncavity P<sup>μ</sup>(w<sub>ij</sub>) ∀j ≠ k. Thus, we replace the sum over multivariate configurations of all noncavity parameters with a single Gaussian integration over the mean-field of noncavity configurations.</p></sec></sec><sec id="s4-1-4-3"><title>Equation 9. Gaussian approximation to the cavity parameter update</title><p><disp-formula id="equ18"><label>(9a)</label><mml:math id="m18"><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mi>μ</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msqrt><mml:mrow><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:msubsup><mml:mi>Δ</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac><mml:mstyle displaystyle="true"><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mi>∞</mml:mi></mml:mrow><mml:mi>∞</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mi>ϕ</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>s</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mi>x</mml:mi><mml:mi>k</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:mstyle><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msubsup><mml:mi>s</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow><mml:mo>−</mml:mo><mml:msubsup><mml:mi>s</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msubsup><mml:mi>Δ</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:msup><mml:mi>d</mml:mi><mml:msubsup><mml:mi>s</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mtext> </mml:mtext><mml:mo>∀</mml:mo><mml:mi>ω</mml:mi><mml:mo>∈</mml:mo><mml:mi>Ω</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ19"><label>(9b)</label><mml:math id="m19"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msubsup><mml:mi>s</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:mstyle><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>u</mml:mi><mml:mi>i</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ20"><label>(9c)</label><mml:math id="m20"><mml:mrow><mml:msubsup><mml:mi>Δ</mml:mi><mml:mi>k</mml:mi><mml:mi>μ</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>≠</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>−</mml:mo><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msubsup><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ21"><label>(9d)</label><mml:math id="m21"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>ω</mml:mi></mml:munder><mml:mi>ω</mml:mi></mml:mstyle><mml:msup><mml:mi>P</mml:mi><mml:mi>μ</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>See Equations 4–14 in <xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al. (2013)</xref> for derivation of <xref ref-type="disp-formula" rid="equ18">Equation 9</xref> and detailed descriptions of the terms in the equation. Note that, BP parameters (temperature factor, β = 2; complexity factor; λ = 5; prior information weight, κ = 5) are adapted for all computations after a systematical analysis of all three parameters (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5</xref>). When prior information is used to construct the models, the complexity term, λ is set to 2.5 for phenotypic nodes in order to approximately match the complexity around the phenotypic nodes and rest of the networks. When the parameter space is sufficiently large, the Gaussian approximation significantly reduces the computational complexity of the problem without loss of overall accuracy. By means of the iterative approach with the mean-field Gaussian approximation, the time-complexity of the problem is strongly reduced and the obstacles imposed by combinatorial complexity are circumvented.</p><sec id="s4-1-4-3-1"><title>BP-guided decimation</title><p>Distinct networks models are instantiated from BP-generated probability distributions with the BP-guided decimation algorithm (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) (<xref ref-type="bibr" rid="bib39">Montanari et al., 2007</xref>). This procedure generates distinct and executable network models. In this study, 4000 distinct network models are generated in each computation.</p></sec><sec id="s4-1-4-3-2"><title>Simulations with in silico perturbations</title><p>Network models are executed with specific in silico perturbations until all system variables {x<sub>i</sub>} reach steady state. The perturbations acting on node, i, are exerted as real-valued, u<sub>i</sub><sup>μ</sup>, vectors in model <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>. The DLSODE integration method (ODEPACK) (<xref ref-type="bibr" rid="bib25">Hindmarsh, 1993</xref>) is used in simulations (default settings with, MF = 10, ATOL = 1e-10, RTOL = 1e-20).</p></sec></sec></sec></sec><sec id="s4-2"><title>Experimental methods</title><sec id="s4-2-1"><title>Cell cultures and perturbation experiments</title><p>All the perturbation experiments are performed using the RAF-inhibitor resistant SkMel-133 cell line. The identity of the SkMel-133 was checked for mislabeling, contamination, and misidentification using a multiplexed PCR/mass spectrometry–based genetic fingerprinting assay run on the HapMap Sequenom platform. In perturbation experiments, the drugs are applied to cell cultures after SkMel-133 cells are grown to about 40% confluence in complete RPMI-1640 medium (10% heat-inactivated fetal bovine serum, 100 units/ml each of penicillin and streptomycin, and incubated at 37°C in 5% CO<sub>2</sub>) in 6-well plates. 24 hr after drug administration, the perturbed cells are harvested. In control experiments (i.e., no drug condition), cells are treated with the DMSO drug vehicle for 24 hr. SkMel-133 cells are perturbed with 12 targeted drugs applied as single agents or in paired combinations (see <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1A,C</xref> for drug list, presumed targets, dosing and sources). In total, cells are treated with 89 unique perturbations. In paired combinations, each drug concentration is selected to inhibit the readout for the presumed target or the downstream effectors by 40% (IC40) as determined by Western blot experiments (<xref ref-type="bibr" rid="bib38">Molinelli, Korkut, Wang et al., 2013</xref>) (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1A</xref>). In single agent perturbations, each drug is applied at two different concentrations, IC40 and 2 × IC40. In validation experiments, (+)JQ1 (Cayman Chemicals, Ann Arbor, MI) and the U.S. Food and Drug Administration (FDA)-approved RAFi PLX4032 (Selleckchem, Houston, TX) are used.</p></sec><sec id="s4-2-2"><title>Reverse phase protein arrays</title><p>Proteomic response profiles to perturbations are measured using RPPA (MD Anderson Cancer Center RPPA Core Facility) (<xref ref-type="bibr" rid="bib62">Tibes et al., 2006</xref>). The cells are lysed 24 hr after drug treatment. For sample preparation, cell pellets are lysed in RPPA buffer (1% Triton X-100, 50 mM HEPES pH7.4, 150 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 1 mM EGTA, 100 mM NaF, 10 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 10% glycerol, freshly added protease and phosphatase inhibitors). After cells are lysed, total protein concentrations in cell lysates are measured with the Bradford assay and the final protein concentrations are adjusted to 1–1.5 mg/ml. Samples are boiled in SDS sample buffer without bromophenol blue for 5 min at 95°C. Cell lysates are spotted on nitrocellulose-coated slides as described in <xref ref-type="bibr" rid="bib62">Tibes et al. (2006)</xref>. Antibody staining intensities are quantified using the MicroVigene automated RPPA module (VigeneTech, Inc., Carlisle, MA) and the standard RPPA protein concentration normalization procedure (<xref ref-type="bibr" rid="bib41">Neeley et al., 2009</xref>) is followed. Three biological replicates are spotted for each sample (i.e., drug condition) on RPPA slides. Each slide is interrogated with a particular antibody, so for each experimental condition 138 proteomic entities (levels of total protein or phoshoprotein) are profiled on 138 slides (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1C</xref>). The proteomic readouts are log normalized with respect to the corresponding untreated condition readouts. We have eliminated those readouts with intra- or inter-slide coefficient of variation &gt;0.15 (i.e., low reproducibility) and low degree of staining by antibodies. 100 proteomic entities are chosen for further analysis.</p></sec><sec id="s4-2-3"><title>Detection of proteomic entities that respond to perturbations</title><p>To generate a constraint set for network inference, we excluded the proteomic entities that do not respond to at least a single perturbation condition from the network models. An iterative signal-to-noise detection algorithm is used for this purpose. At each iteration, the standard deviation of the overall data is computed and data points that deviate for &gt;2.5σ<sub>i</sub> (σ<sub>i</sub>: standard deviation of all data points at iteration i) from the data average are selected as signal (i.e., responding to perturbation). In the next iteration, the σ<sub>i + 1</sub> is computed for all data points except the data points selected as signal in the previous iteration. The σ calculation is iterated until convergence. The proteomic entities that respond to at least a single perturbation condition are selected. This has lead to highly reliable response measurements on a final set of 82 proteomic entities, which have been used in the network models.</p></sec><sec id="s4-2-4"><title>Quantitative phenotypic assays</title><p>All phenotypic measurements are made in perturbation conditions identical to those of proteomic measurements. Cell viability and cell cycle progression are measured using the resazurin assay (72 hr after drug treatment) and flow cytometry analysis (24 hr after drug treatment), respectively. The percentage of cells in the G1, G2/M, and S phases and sub-G1 fraction are recorded based on the respective distribution of DNA content in each phase. For the resazurin assay, each well is treated with the resazurin (Sigma–Aldrich, St. Louis, MO, Catalog #R7017) at a final concentration of 44 μM for 1 hr. The fluorescent signals are measured at 530-nm excitation wavelength and 590-nm emission wavelength. Standard curves of cell numbers are used to calculate the cell numbers in each sample. The cell cycle progression phenotypes are measured with flow cytometry analysis. Cells are seeded in 6-well plates. 72 hr after drug application, cells are harvested by trypsinization, including both suspended and adherent fractions, and washed in cold PBS. Cell nuclei are prepared as described in <xref ref-type="bibr" rid="bib43">Nusse and Kramer (1984)</xref>, and cell cycle distribution was determined by flow cytometric analysis of DNA content using red fluorescence of 488-nm excited ethidium bromide-stained nuclei. The percentage of cells in the G1, G2/M, and S phases and sub-G1 fraction are recorded.</p></sec></sec><sec id="s4-3"><title>Advances in the perturbation biology method</title><p>The improvements in perturbation biology have enabled us to establish our method as a widely applicable tool in genomically informed preclinical studies. Here, we obtained signaling models with increased scope (increased coverage of diverse pathways using a data set 20-fold bigger than previously used data sets) and nominated a particular drug combination to overcome the drug resistance in melanoma. The increased scope of the models is particularly critical for biologists to adopt our method as such models provide a nonreductionist insight into relations between the molecular changes and complex biological phenomena such as drug response, cell fate in diverse conditions, or any other cellular phenotype that can be measured quantitatively. Here, we improved the perturbation biology method and solved three key challenges in network inference to reach scopes and predictive power necessary for addressing complex problems in cancer biology.</p><sec id="s4-3-1"><title>A biologically grounded modeling framework that can be incrementally improved</title><p>Our current modeling scheme can incorporate both quantitative and qualitative prior information through the introduction of a generalized probabilistic error model to the inference cost function (<xref ref-type="disp-formula" rid="equ3">Equations 2</xref>–<xref ref-type="disp-formula" rid="equ15">7</xref>). In the generalized form of the error model, the prize introduced by the priors is sampled from a probability model with a Gaussian distribution (<xref ref-type="disp-formula" rid="equ6">Equation 3</xref>) for the strength (w<sub>ij</sub><sup>prior</sup>) of each prior interaction. A Boltzmann conversion of the prior probability model leads to an error model that is fully compatible with the BP-generated probability distributions, P(w<sub>ij</sub>). Such a generalized error model will be most useful when quantitative prior information is available for the signaling interactions.</p><p>The general error model provides an advantage in building cell-type specific models in diverse but related biological samples. When we build network models for a series of biological systems (e.g., cell lines or patient derived samples) with similar but distinct genomic properties, the BP-generated probability distributions in one cellular system can be extrapolated to another system as a set of probabilistic biases (i.e., priors). The probabilistic extrapolation between different biological samples will significantly reduce the amount of experimental constraints (i.e., perturbation conditions) required to build predictive models while preserving the cell-type specificity for each biological sample studied. This is extremely promising in the context of cancer biology where a model portfolio built from a cohort of patient-derived samples (cell lines or mouse avatars) coupled with genomic profiling can inform treatment decisions for new patients. This bridge between genomic profiles, models, and response to treatment is an open challenge that we think is going to be critical for future precision medicine applications.</p><p>The versatile prior error model introduced here enables us to use known biology in various forms that can be available from previous studies or databases. On one extreme, the error model is simplified and reduced to a step function (<xref ref-type="disp-formula" rid="equ15">Equation 7</xref>). The simplified form of the error model is compatible with the binary priors as are the priors used in this study, which were extracted from the curated signaling databases. Alternatively, one can generate hybrid forms of the cumulative prior error model. Such hybrid models may include (i) the truncated Gaussian model for a subset of priors with quantitative parameters, (ii) the simplified step function form for binary priors, and (iii) alternative forms (e.g., based on a bimodal distribution) for other priors. Although we used the simplified form of the error model and constructed models in a single cell line, we believe the flexibility of the prior error model will be transformative for generating highly predictive models of different biological systems. Such models will subsequently capture the inter-sample variations in response to combinatorial perturbations.</p></sec><sec id="s4-3-2"><title>Systematic integration of prior information</title><p>Development of the PERA algorithm leads to systematic extraction and use of prior interactions, which has a series of advantages over ad hoc introduction of priors in the network modeling scheme. First, currently available network inference algorithms and prior network extraction utilities work at either gene or protein level. Therefore, they are of limited use for inference algorithms that operate on phospho-protein levels. PERA allows users to specify both phospho- and total-protein levels of the genes and provide users with prior knowledge with higher granularity. Second, pathway resources are regularly being updated with newly curated interactions; therefore, our prior knowledge on entities of interest is constantly evolving. PERA can work against new versions of pathway data from Pathway Commons and this enables users to obtain up-to-date prior information for their proteins by simply re-running the application. Third, PERA extracts prior information from pathway data integrated from multiple resources in an automated manner; hence, the interactions extracted from the databases are unbiased compared to the prior knowledge obtained from literature by a single researcher. The algorithm also allows users to specify options (such as the level of phosphorylation site mismatch tolerance and the maximum length between two entities to be considered) for adjusting the complexity and the specificity of the final prior network. Here, an open challenge for future is assigning quantitative confidence scores and statistical information for each prior interaction extracted from databases. Currently, the database-derived priors are in binary form. However, with incorporation of literature co-citation data and experimental co-expression data in different tissues will enable us to estimate the confidence scores and statistical parameters for potential prior interactions.</p></sec><sec id="s4-3-3"><title>Performance improvements that can scale the method to our experimental capabilities</title><p>We optimized the performance of our algorithm by introducing heuristics at key bottlenecks. This was necessitated by 20-fold increase in data points compared to our previous work. One of the key bottlenecks in the modeling scheme is the BP-guided decimation, for which the BP-derived probability distributions are updated after each step (i.e., after sampling all the BP-derived probability distributions and fixing the interaction value for one edge with a probabilistic draw) (see supplementary <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In other words, the posterior probability of a W<sub>ij</sub> is converted to 1. Not surprisingly, the BP-probability for significant fraction of the selected edges is within the range of 0.95–0.99. As fixing an individual edge from P<sup>unfixed</sup>(W<sub>ij</sub>) = 0.95 (P<sup>unfixed</sup>: probability before fixing the edge value) to P<sup>fixed</sup>(W<sub>ij</sub>) = 1 does not significantly alter the probabilistic landscape of the global solution space that involves thousands of other probabilistic events, we updated the global interaction landscape after each decimation step if the P<sup>unfixed</sup>(W<sub>ij</sub>) &lt; 0.95 for the selected edge. However, accumulation of such residual shifts in individual probabilities may lead to a significant change in the global landscape after consecutive iterations of the decimation algorithm. To prevent such inaccuracy in modeling, we updated the probability landscape after five consecutive decimation steps even if P<sup>unfixed</sup>(W<sub>ij</sub>) &gt; 0.95 at each step. In practice, the conditional updating scheme described here provided a &gt;threefold increase in the performance of the BP-decimation algorithm without substantially modifying the sampled probability space.</p></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank NP Gauthier, P Kaushik, ML Miller, DS Marks, A Braunstein, A Pagnani, R Zecchina, M Cokol, and N Rosen for helpful discussions. We thank G Mills for critical reading of the manuscript, helpful discussions, and help with the acquisition of the RPPA data. This work was funded in part by the Center for Cancer Systems Biology grant U54 CA148967 (NIH), the National Resource for Network Biology grant GM103504 (NIH), the Research Resource for Biological Pathways grant U41 HG006623 (NHGRI), and a Melanoma Research Alliance Established Investigator Award.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>AK, Developed the network inference algorithm, conceived and designed the experiments, developed the PERA algorithm, analyzed the data, developed and optimized the code, wrote the paper</p></fn><fn fn-type="con" id="con2"><p>WW, Conceived and designed the experiments, performed the experiments, analyzed the data</p></fn><fn fn-type="con" id="con3"><p>ED, Developed the PERA algorithm, analyzed the data, wrote the paper</p></fn><fn fn-type="con" id="con4"><p>BAA, Developed the PERA algorithm, developed and optimized the code</p></fn><fn fn-type="con" id="con5"><p>XJ, Performed the experiments</p></fn><fn fn-type="con" id="con6"><p>EJM, Developed the network inference algorithm, developed and optimized the code</p></fn><fn fn-type="con" id="con7"><p>ÖB, Developed the PERA algorithm</p></fn><fn fn-type="con" id="con8"><p>DLB, Analyzed the data, coordinated the research activities, revised the paper</p></fn><fn fn-type="con" id="con9"><p>SOS, Analyzed data, designed the website for the perturbation biology method and for interpretation of the data and results in this study</p></fn><fn fn-type="con" id="con10"><p>DBS, Contributed reagents/materials/analysis tools</p></fn><fn fn-type="con" id="con11"><p>CAP, Conceived and designed the experiments, contributed reagents/materials/analysis tools, analyzed and discussed the results</p></fn><fn fn-type="con" id="con12"><p>CS, Conceived and designed the experiments, developed the PERA algorithm, developed the network inference algorithm, analyzed the data, wrote the paper</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.04640.029</object-id><label>Supplementary file 1.</label><caption><p>(<bold>A</bold>) Drugs used in perturbation experiments. (<bold>B</bold>) Proteins that respond to at least one perturbation and exist in models. (<bold>C</bold>) Perturbation conditions. (<bold>D</bold>) Predicted G1-arrest response to combined targeting of c-Myc and other nodes (Perturbations on c-Myc + X). (<bold>E</bold>) Statistical validation of perturbation models. (<bold>F</bold>) Predicted co-targeting strategies in SkMel133 cell line.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04640.029">http://dx.doi.org/10.7554/eLife.04640.029</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-04640-supp1-v1.docx"/></supplementary-material></sec><sec id="s6-1" sec-type="datasets"><title>Major dataset</title><p>The following dataset was generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="http://www.sanderlab.org/pertbio/" source-id-type="uri"><collab collab-type="author">Wang W</collab>, <collab collab-type="author">Korkut A</collab>, <collab collab-type="author">Sander C</collab>, <year>2015</year><x>, </x><source>Phosphoproteomic response to targeted drug combianations in SkMel133 cells</source><x>, </x><ext-link ext-link-type="uri" xlink:href="http://www.sanderlab.org/pertbio/">http://www.sanderlab.org/pertbio/</ext-link><x>, </x><comment>Publicly available online.</comment></related-object></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastas</surname><given-names>JN</given-names></name><name><surname>Kulikauskas</surname><given-names>RM</given-names></name><name><surname>Tamir</surname><given-names>T</given-names></name><name><surname>Rizos</surname><given-names>H</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>von Euw</surname><given-names>EM</given-names></name><name><surname>Yang</surname><given-names>PT</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Haydu</surname><given-names>L</given-names></name><name><surname>Toroni</surname><given-names>RA</given-names></name><name><surname>Lucero</surname><given-names>OM</given-names></name><name><surname>Chien</surname><given-names>AJ</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><year>2014</year><article-title>WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>2877</fpage><lpage>2890</lpage><pub-id pub-id-type="doi">10.1172/JCI70156</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Cary</surname><given-names>MP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year>2006</year><article-title>Pathguide: a pathway resource list</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>D504</fpage><lpage>D506</lpage><pub-id pub-id-type="doi">10.1093/nar/gkj126</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bender</surname><given-names>C</given-names></name><name><surname>von der Heyde</surname><given-names>S</given-names></name><name><surname>Henjes</surname><given-names>F</given-names></name><name><surname>Wiemann</surname><given-names>S</given-names></name><name><surname>Korf</surname><given-names>U</given-names></name><name><surname>Beissbarth</surname><given-names>T</given-names></name></person-group><year>2011</year><article-title>Inferring signalling networks from longitudinal data using sampling based approaches in the R-package ‘ddepn’</article-title><source>BMC Bioinformatics</source><volume>12</volume><fpage>291</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-12-291</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Hirth</surname><given-names>P</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ibrahim</surname><given-names>PN</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Spevak</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Burton</surname><given-names>EA</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Tsang</surname><given-names>G</given-names></name><name><surname>West</surname><given-names>BL</given-names></name><name><surname>Powell</surname><given-names>B</given-names></name><name><surname>Shellooe</surname><given-names>R</given-names></name><name><surname>Marimuthu</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>KY</given-names></name><name><surname>Artis</surname><given-names>DR</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Higgins</surname><given-names>B</given-names></name><name><surname>Iyer</surname><given-names>R</given-names></name><name><surname>D'Andrea</surname><given-names>K</given-names></name><name><surname>Koehler</surname><given-names>A</given-names></name><name><surname>Stumm</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>PS</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Grippo</surname><given-names>J</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name></person-group><year>2010</year><article-title>Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</article-title><source>Nature</source><volume>467</volume><fpage>596</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1038/nature09454</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitkreutz</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Sharom</surname><given-names>JR</given-names></name><name><surname>Boucher</surname><given-names>L</given-names></name><name><surname>Neduva</surname><given-names>V</given-names></name><name><surname>Larsen</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>ZY</given-names></name><name><surname>Breitkreutz</surname><given-names>BJ</given-names></name><name><surname>Stark</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Dewar-Darch</surname><given-names>D</given-names></name><name><surname>Reguly</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Almeida</surname><given-names>R</given-names></name><name><surname>Qin</surname><given-names>ZS</given-names></name><name><surname>Pawson</surname><given-names>T</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Nesvizhskii</surname><given-names>AI</given-names></name><name><surname>Tyers</surname><given-names>M</given-names></name></person-group><year>2010</year><article-title>A global protein kinase and phosphatase interaction network in yeast</article-title><source>Science</source><volume>328</volume><fpage>1043</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1126/science.1176495</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>EG</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Demir</surname><given-names>E</given-names></name><name><surname>Rodchenkov</surname><given-names>I</given-names></name><name><surname>Babur</surname><given-names>O</given-names></name><name><surname>Anwar</surname><given-names>N</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year>2011</year><article-title>Pathway commons, a web resource for biological pathway data</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>D685</fpage><lpage>D690</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1039</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><name><surname>Ascierto</surname><given-names>P</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><name><surname>Jouary</surname><given-names>T</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>O'Day</surname><given-names>SJ</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Nolop</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>B</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><collab>BRIM-3 Study Group</collab></person-group><year>2011</year><article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title><source>The New England Journal of Medicine</source><volume>364</volume><fpage>2507</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103782</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WW</given-names></name><name><surname>Schoeberl</surname><given-names>B</given-names></name><name><surname>Jasper</surname><given-names>PJ</given-names></name><name><surname>Niepel</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>UB</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><year>2009</year><article-title>Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data</article-title><source>Molecular Systems Biology</source><volume>5</volume><fpage>239</fpage><pub-id pub-id-type="doi">10.1038/msb.2008.74</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Henderson</surname><given-names>MJ</given-names></name><name><surname>Kwan</surname><given-names>E</given-names></name><name><surname>Beesley</surname><given-names>AH</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>Bahar</surname><given-names>AY</given-names></name><name><surname>Giles</surname><given-names>J</given-names></name><name><surname>Venn</surname><given-names>NC</given-names></name><name><surname>Pozza</surname><given-names>LD</given-names></name><name><surname>Baker</surname><given-names>DL</given-names></name><name><surname>Marshall</surname><given-names>GM</given-names></name><name><surname>Kees</surname><given-names>UR</given-names></name><name><surname>Haber</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>MD</given-names></name></person-group><year>2007</year><article-title>Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone</article-title><source>Blood</source><volume>110</volume><fpage>632</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-01-067785</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciriello</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>ML</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Senbabaoglu</surname><given-names>Y</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year>2013</year><article-title>Emerging landscape of oncogenic signatures across human cancers</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1127</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/ng.2762</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clegg</surname><given-names>NJ</given-names></name><name><surname>Wongvipat</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>JD</given-names></name><name><surname>Tran</surname><given-names>C</given-names></name><name><surname>Ouk</surname><given-names>S</given-names></name><name><surname>Dilhas</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Grillot</surname><given-names>K</given-names></name><name><surname>Bischoff</surname><given-names>ED</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Aparicio</surname><given-names>A</given-names></name><name><surname>Dorow</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>V</given-names></name><name><surname>Shao</surname><given-names>G</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Sensintaffar</surname><given-names>J</given-names></name><name><surname>Wasielewska</surname><given-names>T</given-names></name><name><surname>Herbert</surname><given-names>MR</given-names></name><name><surname>Bonnefous</surname><given-names>C</given-names></name><name><surname>Darimont</surname><given-names>B</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Smith-Jones</surname><given-names>P</given-names></name><name><surname>Klang</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>ND</given-names></name><name><surname>De Stanchina</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Ouerfelli</surname><given-names>O</given-names></name><name><surname>Rix</surname><given-names>PJ</given-names></name><name><surname>Heyman</surname><given-names>RA</given-names></name><name><surname>Jung</surname><given-names>ME</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Hager</surname><given-names>JH</given-names></name></person-group><year>2012</year><article-title>ARN-509: a novel antiandrogen for prostate cancer treatment</article-title><source>Cancer Research</source><volume>72</volume><fpage>1494</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3948</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>CV</given-names></name></person-group><year>2012</year><article-title>MYC on the path to cancer</article-title><source>Cell</source><volume>149</volume><fpage>22</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.003</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Cox</surname><given-names>C</given-names></name><name><surname>Stephens</surname><given-names>P</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Clegg</surname><given-names>S</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Woffendin</surname><given-names>H</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>Bottomley</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>N</given-names></name><name><surname>Dicks</surname><given-names>E</given-names></name><name><surname>Ewing</surname><given-names>R</given-names></name><name><surname>Floyd</surname><given-names>Y</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Hawes</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Kosmidou</surname><given-names>V</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mould</surname><given-names>C</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Jayatilake</surname><given-names>H</given-names></name><name><surname>Gusterson</surname><given-names>BA</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Shipley</surname><given-names>J</given-names></name><name><surname>Hargrave</surname><given-names>D</given-names></name><name><surname>Pritchard-Jones</surname><given-names>K</given-names></name><name><surname>Maitland</surname><given-names>N</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Riggins</surname><given-names>GJ</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Flanagan</surname><given-names>A</given-names></name><name><surname>Nicholson</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>JW</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Seigler</surname><given-names>HF</given-names></name><name><surname>Darrow</surname><given-names>TL</given-names></name><name><surname>Paterson</surname><given-names>H</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year>2002</year><article-title>Mutations of the BRAF gene in human cancer</article-title><source>Nature</source><volume>417</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/nature00766</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>MA</given-names></name><name><surname>Prinjha</surname><given-names>RK</given-names></name><name><surname>Dittmann</surname><given-names>A</given-names></name><name><surname>Giotopoulos</surname><given-names>G</given-names></name><name><surname>Bantscheff</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>WI</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Chung</surname><given-names>CW</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><name><surname>Savitski</surname><given-names>MM</given-names></name><name><surname>Huthmacher</surname><given-names>C</given-names></name><name><surname>Gudgin</surname><given-names>E</given-names></name><name><surname>Lugo</surname><given-names>D</given-names></name><name><surname>Beinke</surname><given-names>S</given-names></name><name><surname>Chapman</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>EJ</given-names></name><name><surname>Soden</surname><given-names>PE</given-names></name><name><surname>Auger</surname><given-names>KR</given-names></name><name><surname>Mirguet</surname><given-names>O</given-names></name><name><surname>Doehner</surname><given-names>K</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Jeffrey</surname><given-names>P</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Huntly</surname><given-names>BJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year>2011</year><article-title>Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia</article-title><source>Nature</source><volume>478</volume><fpage>529</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/nature10509</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmore</surname><given-names>JE</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Lemieux</surname><given-names>ME</given-names></name><name><surname>Rahl</surname><given-names>PB</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Jacobs</surname><given-names>HM</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name><name><surname>Gilpatrick</surname><given-names>T</given-names></name><name><surname>Paranal</surname><given-names>RM</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Chesi</surname><given-names>M</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>McKeown</surname><given-names>MR</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bergsagel</surname><given-names>PL</given-names></name><name><surname>Ghobrial</surname><given-names>IM</given-names></name><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Mitsiades</surname><given-names>CS</given-names></name></person-group><year>2011</year><article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title><source>Cell</source><volume>146</volume><fpage>904</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.017</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demir</surname><given-names>E</given-names></name><name><surname>Cary</surname><given-names>MP</given-names></name><name><surname>Paley</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>K</given-names></name><name><surname>Lemer</surname><given-names>C</given-names></name><name><surname>Vastrik</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>GN</given-names></name><name><surname>D'Eustachio</surname><given-names>P</given-names></name><name><surname>Schaefer</surname><given-names>C</given-names></name><name><surname>Luciano</surname><given-names>J</given-names></name><name><surname>Schacherer</surname><given-names>F</given-names></name><name><surname>Martinez-Flores</surname><given-names>I</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Jimenez-Jacinto</surname><given-names>V</given-names></name><name><surname>Joshi-Tope</surname><given-names>G</given-names></name><name><surname>Kandasamy</surname><given-names>K</given-names></name><name><surname>Lopez-Fuentes</surname><given-names>AC</given-names></name><name><surname>Mi</surname><given-names>H</given-names></name><name><surname>Pichler</surname><given-names>E</given-names></name><name><surname>Rodchenkov</surname><given-names>I</given-names></name><name><surname>Splendiani</surname><given-names>A</given-names></name><name><surname>Tkachev</surname><given-names>S</given-names></name><name><surname>Zucker</surname><given-names>J</given-names></name><name><surname>Gopinath</surname><given-names>G</given-names></name><name><surname>Rajasimha</surname><given-names>H</given-names></name><name><surname>Ramakrishnan</surname><given-names>R</given-names></name><name><surname>Shah</surname><given-names>I</given-names></name><name><surname>Syed</surname><given-names>M</given-names></name><name><surname>Anwar</surname><given-names>N</given-names></name><name><surname>Babur</surname><given-names>O</given-names></name><name><surname>Blinov</surname><given-names>M</given-names></name><name><surname>Brauner</surname><given-names>E</given-names></name><name><surname>Corwin</surname><given-names>D</given-names></name><name><surname>Donaldson</surname><given-names>S</given-names></name><name><surname>Gibbons</surname><given-names>F</given-names></name><name><surname>Goldberg</surname><given-names>R</given-names></name><name><surname>Hornbeck</surname><given-names>P</given-names></name><name><surname>Luna</surname><given-names>A</given-names></name><name><surname>Murray-Rust</surname><given-names>P</given-names></name><name><surname>Neumann</surname><given-names>E</given-names></name><name><surname>Ruebenacker</surname><given-names>O</given-names></name><name><surname>Samwald</surname><given-names>M</given-names></name><name><surname>van Iersel</surname><given-names>M</given-names></name><name><surname>Wimalaratne</surname><given-names>S</given-names></name><name><surname>Allen</surname><given-names>K</given-names></name><name><surname>Braun</surname><given-names>B</given-names></name><name><surname>Whirl-Carrillo</surname><given-names>M</given-names></name><name><surname>Cheung</surname><given-names>KH</given-names></name><name><surname>Dahlquist</surname><given-names>K</given-names></name><name><surname>Finney</surname><given-names>A</given-names></name><name><surname>Gillespie</surname><given-names>M</given-names></name><name><surname>Glass</surname><given-names>E</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Haw</surname><given-names>R</given-names></name><name><surname>Honig</surname><given-names>M</given-names></name><name><surname>Hubaut</surname><given-names>O</given-names></name><name><surname>Kane</surname><given-names>D</given-names></name><name><surname>Krupa</surname><given-names>S</given-names></name><name><surname>Kutmon</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>J</given-names></name><name><surname>Marks</surname><given-names>D</given-names></name><name><surname>Merberg</surname><given-names>D</given-names></name><name><surname>Petri</surname><given-names>V</given-names></name><name><surname>Pico</surname><given-names>A</given-names></name><name><surname>Ravenscroft</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Sunshine</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Whaley</surname><given-names>R</given-names></name><name><surname>Letovksy</surname><given-names>S</given-names></name><name><surname>Buetow</surname><given-names>KH</given-names></name><name><surname>Rzhetsky</surname><given-names>A</given-names></name><name><surname>Schachter</surname><given-names>V</given-names></name><name><surname>Sobral</surname><given-names>BS</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>McWeeney</surname><given-names>S</given-names></name><name><surname>Aladjem</surname><given-names>M</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Collado-Vides</surname><given-names>J</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Hucka</surname><given-names>M</given-names></name><name><surname>Le Novère</surname><given-names>N</given-names></name><name><surname>Maltsev</surname><given-names>N</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Wingender</surname><given-names>E</given-names></name><name><surname>Karp</surname><given-names>PD</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name></person-group><year>2010</year><article-title>The BioPAX community standard for pathway data sharing</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>935</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1038/nbt.1666</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Cetintas</surname><given-names>A</given-names></name><name><surname>Demir</surname><given-names>E</given-names></name><name><surname>Babur</surname><given-names>O</given-names></name></person-group><year>2009</year><article-title>Algorithms for effective querying of compound graph-based pathway databases</article-title><source>BMC Bioinformatics</source><volume>10</volume><fpage>376</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-10-376</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domcke</surname><given-names>S</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year>2013</year><article-title>Evaluating cell lines as tumour models by comparison of genomic profiles</article-title><source>Nature Communications</source><volume>4</volume><fpage>2126</fpage><pub-id pub-id-type="doi">10.1038/ncomms3126</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippakopoulos</surname><given-names>P</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name></person-group><year>2014</year><article-title>Targeting bromodomains: epigenetic readers of lysine acetylation</article-title><source>Nature Reviews. Drug Discovery</source><volume>13</volume><fpage>337</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1038/nrd4286</pub-id></element-citation></ref><ref id="bib19a"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiskus</surname><given-names>W</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>B</given-names></name><name><surname>Devaraj</surname><given-names>SG</given-names></name><name><surname>Leveque</surname><given-names>C</given-names></name><name><surname>Portier</surname><given-names>BP</given-names></name><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Bhalla</surname><given-names>KN</given-names></name></person-group><year>2014</year><article-title>BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD</article-title><source>Molecular Cancer Therapeutics</source><volume>13</volume><fpage>2315</fpage><lpage>2327</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0258</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>JB</given-names></name><name><surname>Schoeberl</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>UB</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><year>2006</year><article-title>Systems biology and combination therapy in the quest for clinical efficacy</article-title><source>Nature Chemical Biology</source><volume>2</volume><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1038/nchembio817</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Infante</surname><given-names>JR</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Kefford</surname><given-names>RF</given-names></name><name><surname>Sosman</surname><given-names>J</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Schuchter</surname><given-names>L</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Kudchadkar</surname><given-names>R</given-names></name><name><surname>Burris</surname><given-names>HA</given-names><suffix>III</suffix></name><name><surname>Falchook</surname><given-names>G</given-names></name><name><surname>Algazi</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Lebowitz</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Allred</surname><given-names>A</given-names></name><name><surname>Ouellet</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name></person-group><year>2012a</year><article-title>Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</article-title><source>New England Journal of Medicine</source><volume>367</volume><fpage>1694</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1210093</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name><name><surname>Nathan</surname><given-names>P</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Milhem</surname><given-names>M</given-names></name><name><surname>Demidov</surname><given-names>LV</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>Mohr</surname><given-names>P</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Trefzer</surname><given-names>U</given-names></name><name><surname>Larkin</surname><given-names>JM</given-names></name><name><surname>Utikal</surname><given-names>J</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Nyakas</surname><given-names>M</given-names></name><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Becker</surname><given-names>JC</given-names></name><name><surname>Casey</surname><given-names>M</given-names></name><name><surname>Sherman</surname><given-names>LJ</given-names></name><name><surname>Wu</surname><given-names>FS</given-names></name><name><surname>Ouellet</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>AM</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><collab>METRIC Study Group</collab></person-group><year>2012b</year><article-title>Improved survival with MEK inhibition in BRAF-mutated melanoma</article-title><source>The New England Journal of Medicine</source><volume>367</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1203421</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name></person-group><year>2012</year><article-title>Circumventing cancer drug resistance in the era of personalized medicine</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>214</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0012</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haluska</surname><given-names>FG</given-names></name><name><surname>Tsao</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Haluska</surname><given-names>FS</given-names></name><name><surname>Lazar</surname><given-names>A</given-names></name><name><surname>Goel</surname><given-names>V</given-names></name></person-group><year>2006</year><article-title>Genetic alterations in signaling pathways in melanoma</article-title><source>Clinical Cancer Research</source><volume>12</volume><fpage>2301s</fpage><lpage>2307s</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2518</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hindmarsh</surname><given-names>AC</given-names></name></person-group><year>1993</year><article-title>ODEPACK, a systematized collection of ODE solvers</article-title><person-group person-group-type="editor"><name><surname>Stepleman</surname><given-names>RS</given-names></name><name><surname>Carver</surname><given-names>M</given-names></name><name><surname>Peskin</surname><given-names>R</given-names></name><name><surname>Ames</surname><given-names>WF</given-names></name><name><surname>Vichnevetsky</surname><given-names>R</given-names></name></person-group><source>Scientific Computing</source><publisher-loc>Amsterdam</publisher-loc><publisher-name>North-Holland Publishing Company</publisher-name><fpage>55</fpage><lpage>64</lpage></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>CC</given-names></name><name><surname>Hilsenbeck</surname><given-names>SG</given-names></name><name><surname>Ward</surname><given-names>R</given-names></name><name><surname>Rimawi</surname><given-names>MF</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Shou</surname><given-names>J</given-names></name><name><surname>Bissell</surname><given-names>MJ</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Schiff</surname><given-names>R</given-names></name></person-group><year>2011</year><article-title>beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib</article-title><source>Breast Cancer Research</source><volume>13</volume><fpage>R84</fpage><pub-id pub-id-type="doi">10.1186/bcr2936</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaynes</surname><given-names>ET</given-names></name></person-group><year>1957</year><article-title>Information theory and statistical mechanics</article-title><source>Physical Review</source><volume>106</volume><fpage>620</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1103/PhysRev.106.620</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Thomas</surname><given-names>SR</given-names></name><name><surname>Wardwell</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Emery</surname><given-names>CM</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Cogdill</surname><given-names>AP</given-names></name><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Murray</surname><given-names>RR</given-names></name><name><surname>Salehi-Ashtiani</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Alkan</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>JL</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Finan</surname><given-names>PM</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Golub</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year>2010</year><article-title>COT drives resistance to RAF inhibition through MAP kinase pathway reactivation</article-title><source>Nature</source><volume>468</volume><fpage>968</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1038/nature09627</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klinger</surname><given-names>B</given-names></name><name><surname>Sieber</surname><given-names>A</given-names></name><name><surname>Fritsche-Guenther</surname><given-names>R</given-names></name><name><surname>Witzel</surname><given-names>F</given-names></name><name><surname>Berry</surname><given-names>L</given-names></name><name><surname>Schumacher</surname><given-names>D</given-names></name><name><surname>Yan</surname><given-names>YB</given-names></name><name><surname>Durek</surname><given-names>P</given-names></name><name><surname>Merchant</surname><given-names>M</given-names></name><name><surname>Schafer</surname><given-names>R</given-names></name><name><surname>Sers</surname><given-names>C</given-names></name><name><surname>Blüthgen</surname><given-names>N</given-names></name></person-group><year>2013</year><article-title>Network quantification of EGFR signaling unveils potential for targeted combination therapy</article-title><source>Molecular Systems Biology</source><volume>9</volume><fpage>673</fpage><pub-id pub-id-type="doi">10.1038/msb.2013.29</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Novere</surname><given-names>N</given-names></name><name><surname>Hucka</surname><given-names>M</given-names></name><name><surname>Mi</surname><given-names>H</given-names></name><name><surname>Moodie</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>F</given-names></name><name><surname>Sorokin</surname><given-names>A</given-names></name><name><surname>Demir</surname><given-names>E</given-names></name><name><surname>Wegner</surname><given-names>K</given-names></name><name><surname>Aladjem</surname><given-names>MI</given-names></name><name><surname>Wimalaratne</surname><given-names>SM</given-names></name><name><surname>Bergman</surname><given-names>FT</given-names></name><name><surname>Gauges</surname><given-names>R</given-names></name><name><surname>Ghazal</surname><given-names>P</given-names></name><name><surname>Kawaji</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Villéger</surname><given-names>A</given-names></name><name><surname>Boyd</surname><given-names>SE</given-names></name><name><surname>Calzone</surname><given-names>L</given-names></name><name><surname>Courtot</surname><given-names>M</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Freeman</surname><given-names>TC</given-names></name><name><surname>Funahashi</surname><given-names>A</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Jouraku</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kolpakov</surname><given-names>F</given-names></name><name><surname>Luna</surname><given-names>A</given-names></name><name><surname>Sahle</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Watterson</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Goryanin</surname><given-names>I</given-names></name><name><surname>Kell</surname><given-names>DB</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Sauro</surname><given-names>H</given-names></name><name><surname>Snoep</surname><given-names>JL</given-names></name><name><surname>Kohn</surname><given-names>K</given-names></name><name><surname>Kitano</surname><given-names>H</given-names></name></person-group><year>2009</year><article-title>The systems biology graphical notation</article-title><source>Nature Biotechnology</source><volume>27</volume><fpage>735</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1038/nbt.1558</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lito</surname><given-names>P</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Joseph</surname><given-names>EW</given-names></name><name><surname>Tadi</surname><given-names>M</given-names></name><name><surname>Halilovic</surname><given-names>E</given-names></name><name><surname>Zubrowski</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>WL</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Chandarlapaty</surname><given-names>S</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Fagin</surname><given-names>JA</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year>2012</year><article-title>Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas</article-title><source>Cancer Cell</source><volume>22</volume><fpage>668</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.10.009</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lockwood</surname><given-names>WW</given-names></name><name><surname>Zejnullahu</surname><given-names>K</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name></person-group><year>2012</year><article-title>Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>109</volume><fpage>19408</fpage><lpage>19413</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216363109</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Stroyakovskiy</surname><given-names>D</given-names></name><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Levchenko</surname><given-names>E</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Jouary</surname><given-names>T</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Chiarion Sileni</surname><given-names>V</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><name><surname>Mandalà</surname><given-names>M</given-names></name><name><surname>Millward</surname><given-names>M</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Bondarenko</surname><given-names>I</given-names></name><name><surname>Haanen</surname><given-names>JB</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Utikal</surname><given-names>J</given-names></name><name><surname>Ferraresi</surname><given-names>V</given-names></name><name><surname>Kovalenko</surname><given-names>N</given-names></name><name><surname>Mohr</surname><given-names>P</given-names></name><name><surname>Probachai</surname><given-names>V</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Nathan</surname><given-names>P</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>DeMarini</surname><given-names>DJ</given-names></name><name><surname>Irani</surname><given-names>JG</given-names></name><name><surname>Casey</surname><given-names>M</given-names></name><name><surname>Ouellet</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>AM</given-names></name><name><surname>Le</surname><given-names>N</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Flaherty</surname><given-names>K</given-names></name></person-group><year>2014</year><article-title>Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma</article-title><source>The New England Journal of Medicine</source><volume>371</volume><fpage>1877</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1406037</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loven</surname><given-names>J</given-names></name><name><surname>Hoke</surname><given-names>HA</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Lau</surname><given-names>A</given-names></name><name><surname>Orlando</surname><given-names>DA</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>TI</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year>2013</year><article-title>Selective inhibition of tumor oncogenes by disruption of super-enhancers</article-title><source>Cell</source><volume>153</volume><fpage>320</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.036</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>Gopinath</surname><given-names>G</given-names></name><name><surname>Gillespie</surname><given-names>M</given-names></name><name><surname>Caudy</surname><given-names>M</given-names></name><name><surname>Croft</surname><given-names>D</given-names></name><name><surname>de Bono</surname><given-names>B</given-names></name><name><surname>Garapati</surname><given-names>P</given-names></name><name><surname>Hemish</surname><given-names>J</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name><name><surname>Jassal</surname><given-names>B</given-names></name><name><surname>Gopinath</surname><given-names>GR</given-names></name><name><surname>Wu</surname><given-names>GR</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Stein</surname><given-names>L</given-names></name></person-group><year>2009</year><article-title>Reactome knowledgebase of human biological pathways and processes</article-title><source>Nucleic Acids Research</source><volume>37</volume><fpage>D619</fpage><lpage>D622</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn863</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>JA</given-names></name><name><surname>Conery</surname><given-names>AR</given-names></name><name><surname>Bryant</surname><given-names>BM</given-names></name><name><surname>Sandy</surname><given-names>P</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Mele</surname><given-names>DA</given-names></name><name><surname>Bergeron</surname><given-names>L</given-names></name><name><surname>Sims</surname><given-names>RJ</given-names><suffix>III</suffix></name></person-group><year>2011</year><article-title>Targeting MYC dependence in cancer by inhibiting BET bromodomains</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>108</volume><fpage>16669</fpage><lpage>16674</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108190108</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>ML</given-names></name><name><surname>Molinelli</surname><given-names>EJ</given-names></name><name><surname>Nair</surname><given-names>JS</given-names></name><name><surname>Sheikh</surname><given-names>T</given-names></name><name><surname>Samy</surname><given-names>R</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Korkut</surname><given-names>A</given-names></name><name><surname>Crago</surname><given-names>AM</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year>2013</year><article-title>Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets</article-title><source>Science Signaling</source><volume>6</volume><fpage>ra85</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2004014</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinelli</surname><given-names>EJ</given-names></name><name><surname>Korkut</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>ML</given-names></name><name><surname>Gauthier</surname><given-names>NP</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Kaushik</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Mills</surname><given-names>G</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Weigt</surname><given-names>M</given-names></name><name><surname>Braunstein</surname><given-names>A</given-names></name><name><surname>Pagnani</surname><given-names>A</given-names></name><name><surname>Zecchina</surname><given-names>R</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year>2013</year><article-title>Perturbation biology: inferring signaling networks in cellular systems</article-title><source>PLOS Computational Biology</source><volume>9</volume><fpage>e1003290</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003290</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montanari</surname><given-names>A</given-names></name><name><surname>Ricci-Tersenghi</surname><given-names>F</given-names></name><name><surname>Semerjian</surname><given-names>G</given-names></name></person-group><year>2007</year><article-title>Solving constraint satisfaction problems through belief propagation-guided decimation</article-title><comment>arXiv, 0709.1667. <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/0709.1667">http://arxiv.org/abs/0709.1667</ext-link></comment></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nazarian</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Koya</surname><given-names>RC</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Attar</surname><given-names>N</given-names></name><name><surname>Sazegar</surname><given-names>H</given-names></name><name><surname>Chodon</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>SF</given-names></name><name><surname>McArthur</surname><given-names>G</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name></person-group><year>2010</year><article-title>Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</article-title><source>Nature</source><volume>468</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09626</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neeley</surname><given-names>ES</given-names></name><name><surname>Kornblau</surname><given-names>SM</given-names></name><name><surname>Coombes</surname><given-names>KR</given-names></name><name><surname>Baggerly</surname><given-names>KA</given-names></name></person-group><year>2009</year><article-title>Variable slope normalization of reverse phase protein arrays</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1384</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp174</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelander</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>She</surname><given-names>QB</given-names></name><name><surname>Pratilas</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Gennemark</surname><given-names>P</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year>2008</year><article-title>Models from experiments: combinatorial drug perturbations of cancer cells</article-title><source>Molecular Systems Biology</source><volume>4</volume><fpage>216</fpage><pub-id pub-id-type="doi">10.1038/msb.2008.53</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>M</given-names></name><name><surname>Kramer</surname><given-names>J</given-names></name></person-group><year>1984</year><article-title>Flow cytometric analysis of micronuclei found in cells after irradiation</article-title><source>Cytometry</source><volume>5</volume><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/cyto.990050105</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Reilly</surname><given-names>KE</given-names></name><name><surname>Rojo</surname><given-names>F</given-names></name><name><surname>She</surname><given-names>QB</given-names></name><name><surname>Solit</surname><given-names>D</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Lane</surname><given-names>H</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Ludwig</surname><given-names>DL</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year>2006</year><article-title>mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</article-title><source>Cancer Research</source><volume>66</volume><fpage>1500</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2925</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oates</surname><given-names>CJ</given-names></name><name><surname>Dondelinger</surname><given-names>F</given-names></name><name><surname>Bayani</surname><given-names>N</given-names></name><name><surname>Korkola</surname><given-names>J</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name></person-group><year>2014</year><article-title>Causal network inference using biochemical kinetics</article-title><source>Bioinformatics</source><volume>30</volume><fpage>I468</fpage><lpage>I474</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu452</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Politi</surname><given-names>KA</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Somwar</surname><given-names>R</given-names></name><name><surname>Zakowski</surname><given-names>MF</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name></person-group><year>2005</year><article-title>Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</article-title><source>PLOS Medicine</source><volume>2</volume><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0020073</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year>2010</year><article-title>RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</article-title><source>Nature</source><volume>464</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nature08902</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prahallad</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Zecchin</surname><given-names>D</given-names></name><name><surname>Beijersbergen</surname><given-names>RL</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><year>2012</year><article-title>Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</article-title><source>Nature</source><volume>483</volume><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nature10868</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year>2009</year><article-title>(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>106</volume><fpage>4519</fpage><lpage>4524</lpage><pub-id pub-id-type="doi">10.1073/pnas.0900780106</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puissant</surname><given-names>A</given-names></name><name><surname>Frumm</surname><given-names>SM</given-names></name><name><surname>Alexe</surname><given-names>G</given-names></name><name><surname>Bassil</surname><given-names>CF</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Chanthery</surname><given-names>YH</given-names></name><name><surname>Nekritz</surname><given-names>EA</given-names></name><name><surname>Zeid</surname><given-names>R</given-names></name><name><surname>Gustafson</surname><given-names>WC</given-names></name><name><surname>Greninger</surname><given-names>P</given-names></name><name><surname>Garnett</surname><given-names>MJ</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Benes</surname><given-names>CH</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Weiss</surname><given-names>WA</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Stegmaier</surname><given-names>K</given-names></name></person-group><year>2013</year><article-title>Targeting MYCN in neuroblastoma by BET bromodomain inhibition</article-title><source>Cancer Discovery</source><volume>3</volume><fpage>308</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0418</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rother</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name></person-group><year>2009</year><article-title>Molecular markers of tumor progression in melanoma</article-title><source>Current genomics</source><volume>10</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.2174/138920209788488526</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saez-Rodriguez</surname><given-names>J</given-names></name><name><surname>Alexopoulos</surname><given-names>LG</given-names></name><name><surname>Epperlein</surname><given-names>J</given-names></name><name><surname>Samaga</surname><given-names>R</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Klamt</surname><given-names>S</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><year>2009</year><article-title>Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction</article-title><source>Molecular Systems Biology</source><volume>5</volume><fpage>331</fpage><pub-id pub-id-type="doi">10.1038/msb.2009.87</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saez-Rodriguez</surname><given-names>J</given-names></name><name><surname>Alexopoulos</surname><given-names>LG</given-names></name><name><surname>Zhang</surname><given-names>MS</given-names></name><name><surname>Morris</surname><given-names>MK</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name></person-group><year>2011</year><article-title>Comparing signaling networks between normal and transformed hepatocytes using discrete logical models</article-title><source>Cancer Research</source><volume>71</volume><fpage>5400</fpage><lpage>5411</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-4453</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>CF</given-names></name><name><surname>Anthony</surname><given-names>K</given-names></name><name><surname>Krupa</surname><given-names>S</given-names></name><name><surname>Buchoff</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>M</given-names></name><name><surname>Hannay</surname><given-names>T</given-names></name><name><surname>Buetow</surname><given-names>KH</given-names></name></person-group><year>2009</year><article-title>PID: the pathway interaction database</article-title><source>Nucleic Acids Research</source><volume>37</volume><fpage>D674</fpage><lpage>D679</lpage><pub-id pub-id-type="doi">10.1093/nar/gkn653</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>J</given-names></name><name><surname>Strimmer</surname><given-names>K</given-names></name></person-group><year>2005</year><article-title>A shrinkage approach to large-scale covariance matrix estimation and implications for functional genomics</article-title><source>Statistical Applications in Genetics and Molecular Biology</source><volume>4</volume><fpage>Article32</fpage><pub-id pub-id-type="doi">10.2202/1544-6115.1175</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segura</surname><given-names>MF</given-names></name><name><surname>Fontanals-Cirera</surname><given-names>B</given-names></name><name><surname>Gaziel-Sovran</surname><given-names>A</given-names></name><name><surname>Guijarro</surname><given-names>MV</given-names></name><name><surname>Hanniford</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>GT</given-names></name><name><surname>Gonzalez-Gomez</surname><given-names>P</given-names></name><name><surname>Morante</surname><given-names>M</given-names></name><name><surname>Jubierre</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>WJ</given-names></name><name><surname>Darvishian</surname><given-names>F</given-names></name><name><surname>Ohlmeyer</surname><given-names>M</given-names></name><name><surname>Osman</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>MM</given-names></name><name><surname>Hernando</surname><given-names>E</given-names></name></person-group><year>2013</year><article-title>BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy</article-title><source>Cancer Research</source><volume>73</volume><fpage>6264</fpage><lpage>6276</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0122-T</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK)</article-title><source>Nature Methods</source><volume>3</volume><fpage>981</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1038/nmeth972</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Sawai</surname><given-names>A</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Basso</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Lobo</surname><given-names>JM</given-names></name><name><surname>She</surname><given-names>Y</given-names></name><name><surname>Osman</surname><given-names>I</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Sebolt-Leopold</surname><given-names>J</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year>2006</year><article-title>BRAF mutation predicts sensitivity to MEK inhibition</article-title><source>Nature</source><volume>439</volume><fpage>358</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nature04304</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Schuchter</surname><given-names>L</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Pavlick</surname><given-names>AC</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Moschos</surname><given-names>SJ</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name><name><surname>Kefford</surname><given-names>R</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Lewis</surname><given-names>KD</given-names></name><name><surname>Amaravadi</surname><given-names>RK</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Lawrence</surname><given-names>HJ</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nolop</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>Joe</surname><given-names>AK</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year>2012</year><article-title>Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>707</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1112302</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soucek</surname><given-names>L</given-names></name><name><surname>Whitfield</surname><given-names>J</given-names></name><name><surname>Martins</surname><given-names>CP</given-names></name><name><surname>Finch</surname><given-names>AJ</given-names></name><name><surname>Murphy</surname><given-names>DJ</given-names></name><name><surname>Sodir</surname><given-names>NM</given-names></name><name><surname>Karnezis</surname><given-names>AN</given-names></name><name><surname>Swigart</surname><given-names>LB</given-names></name><name><surname>Nasi</surname><given-names>S</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name></person-group><year>2008</year><article-title>Modelling Myc inhibition as a cancer therapy</article-title><source>Nature</source><volume>455</volume><fpage>679</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1038/nature07260</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Heynen</surname><given-names>GJ</given-names></name><name><surname>Prahallad</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Haanen</surname><given-names>J</given-names></name><name><surname>Blank</surname><given-names>C</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><name><surname>Willems</surname><given-names>SM</given-names></name><name><surname>Zecchin</surname><given-names>D</given-names></name><name><surname>Hobor</surname><given-names>S</given-names></name><name><surname>Bajpe</surname><given-names>PK</given-names></name><name><surname>Lieftink</surname><given-names>C</given-names></name><name><surname>Mateus</surname><given-names>C</given-names></name><name><surname>Vagner</surname><given-names>S</given-names></name><name><surname>Grernrum</surname><given-names>W</given-names></name><name><surname>Hofland</surname><given-names>I</given-names></name><name><surname>Schlicker</surname><given-names>A</given-names></name><name><surname>Wessels</surname><given-names>LF</given-names></name><name><surname>Beijersbergen</surname><given-names>RL</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><year>2014</year><article-title>Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</article-title><source>Nature</source><volume>508</volume><fpage>118</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/nature13121</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibes</surname><given-names>R</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Hennessy</surname><given-names>B</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Kornblau</surname><given-names>SM</given-names></name></person-group><year>2006</year><article-title>Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells</article-title><source>Molecular Cancer Therapeutics</source><volume>5</volume><fpage>2512</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0334</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Wagle</surname><given-names>N</given-names></name><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Treacy</surname><given-names>DJ</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Goetz</surname><given-names>EM</given-names></name><name><surname>Place</surname><given-names>CS</given-names></name><name><surname>Taylor-Weiner</surname><given-names>A</given-names></name><name><surname>Whittaker</surname><given-names>S</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Rosenberg</surname><given-names>M</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Farlow</surname><given-names>D</given-names></name><name><surname>Zimmer</surname><given-names>L</given-names></name><name><surname>Hillen</surname><given-names>U</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Goldinger</surname><given-names>SM</given-names></name><name><surname>Ugurel</surname><given-names>S</given-names></name><name><surname>Gogas</surname><given-names>HJ</given-names></name><name><surname>Egberts</surname><given-names>F</given-names></name><name><surname>Berking</surname><given-names>C</given-names></name><name><surname>Trefzer</surname><given-names>U</given-names></name><name><surname>Loquai</surname><given-names>C</given-names></name><name><surname>Weide</surname><given-names>B</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><collab>Dermatologic Cooperative Oncology Group of Germany (DeCOG)</collab></person-group><year>2014</year><article-title>The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0617</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva</surname><given-names>J</given-names></name><name><surname>Vultur</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>JT</given-names></name><name><surname>Somasundaram</surname><given-names>R</given-names></name><name><surname>Fukunaga-Kalabis</surname><given-names>M</given-names></name><name><surname>Cipolla</surname><given-names>AK</given-names></name><name><surname>Wubbenhorst</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Kee</surname><given-names>D</given-names></name><name><surname>Santiago-Walker</surname><given-names>AE</given-names></name><name><surname>Letrero</surname><given-names>R</given-names></name><name><surname>D'Andrea</surname><given-names>K</given-names></name><name><surname>Pushparajan</surname><given-names>A</given-names></name><name><surname>Hayden</surname><given-names>JE</given-names></name><name><surname>Brown</surname><given-names>KD</given-names></name><name><surname>Laquerre</surname><given-names>S</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><year>2010</year><article-title>Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K</article-title><source>Cancer Cell</source><volume>18</volume><fpage>683</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.11.023</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagle</surname><given-names>N</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Treacy</surname><given-names>DJ</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Cooper</surname><given-names>ZA</given-names></name><name><surname>Taylor-Weiner</surname><given-names>A</given-names></name><name><surname>Rosenberg</surname><given-names>M</given-names></name><name><surname>Goetz</surname><given-names>EM</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Farlow</surname><given-names>DN</given-names></name><name><surname>Friedrich</surname><given-names>DC</given-names></name><name><surname>Anderka</surname><given-names>K</given-names></name><name><surname>Perrin</surname><given-names>D</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Kryukov</surname><given-names>G</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Lawrence</surname><given-names>DP</given-names></name><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year>2013</year><article-title>MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0631</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>F</given-names></name><name><surname>Persaud</surname><given-names>Y</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Janakiraman</surname><given-names>M</given-names></name><name><surname>She</surname><given-names>QB</given-names></name><name><surname>Gallardo</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Hefter</surname><given-names>B</given-names></name><name><surname>Dolgalev</surname><given-names>I</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>De Stanchina</surname><given-names>E</given-names></name><name><surname>Cobrinik</surname><given-names>D</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Wolchok</surname><given-names>J</given-names></name><name><surname>Houghton</surname><given-names>A</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name></person-group><year>2012</year><article-title>Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF</article-title><source>Oncogene</source><volume>31</volume><fpage>446</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.250</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Hemann</surname><given-names>MT</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name></person-group><year>2014</year><article-title>Intratumor heterogeneity alters most effective drugs in designed combinations</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>111</volume><fpage>10773</fpage><lpage>10778</lpage><pub-id pub-id-type="doi">10.1073/pnas.1323934111</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.04640.030</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Airoldi</surname><given-names>Edoardo M</given-names></name><role>Reviewing editor</role><aff><institution>Harvard University</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for sending your work entitled “Perturbation biology models predict c-Myc as an effective co-target in RAF inhibitor resistant melanoma cells” for consideration at <italic>eLife</italic>. Your article has been favorably evaluated by Aviv Regev (Senior editor), a Reviewing Editor, and two additional reviewers.</p><p>The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.</p><p>The editorial team has identified two areas of major concern: (1) novelty of the approach and (2) biological significance.</p><p>Regarding novelty of the approach, a portion of the most interesting methodological innovations has been already published by a subset of the authors. The pre-processing PERA step is new, and so are a number of other technical advances. In this paper, the authors extended the scope of the analysis substantially (phosphoprotein antibodies from 16 to 138, perturbation conditions from 44 to 89, and phenotypes from 1 to 5), and we appreciate that this extension is critical for biologists to adopt such approaches. However, the authors fail to clearly present the innovations over previous work. The authors should make an effort, perhaps in a dedicated subsection under Methods, to offer a nuanced discussion of the approach stating how it supports scientific discovery, what is novel relative to the earlier studies, and what are the open challenges. Overall the approach is technically solid and well motivated, and <italic>eLife</italic> readers will benefit from such a discussion in the context of the new and extensive data set.</p><p>Regarding biological significance, the reviewers all agree that the authors do not clearly address how their results advance our understanding of the biology, nor provide any novel biological insights. It is very important that any conceptual novelty is highlighted in the revised manuscript.</p><p>Other serious concerns include limitations of the approach with respect to predictions (reviewer 2, please address this in the response and in the manuscript), and lack of a convincing statistical validation (e.g., frequentist coverage of the predictions in a realistic simulation study – where data are generated using parameters estimated from the real data). We would like to see these addressed in the revision as well.</p><p>Overall, this is a solid piece of work, and we look forward to receiving a revision.</p><p><italic>Reviewer #1:</italic></p><p>The authors applied belief propagation to data from systematic pharmacological perturbations and generated network models of signaling in melanoma cells. The authors used these models to predict cellular responses to untested drug perturbations. Simulating the models, the authors made predictions for effective combinations of perturbation. The authors argue that one of these predictions, that co-targeting c-Myc with MEK or RAF is synergistic, is non trivial and go on to demonstrate experimentally a synergistic effect of co-treating.</p><p>Conceptual and high-level feedback:</p><p>In my opinion, the most significant and general result of this work is showing the promise of genomically-informed preclinical trials and providing a concrete example of a synergistic pharmacological treatment inhibiting the cell division of melanoma cells. The experimental design and the network inference methodology seem careful and well executed. The results appear convincing. On the down-side, I do not see much conceptual novelty or results contributing to our understanding of the biology. It is also not clear to me that the initial synergistic effect of co-targeting, which is interesting and explored in details, will actually prevent the development of drug-resistance over the long term in a clinical application. I invite the authors to emphasize any conceptual advances in their work and new biological conclusions that I may be missing. I think that conceptual advances would contribute the most to elevating the significance and general interest in this work.</p><p>[Minor comments not shown.]</p><p><italic>Reviewer #2:</italic></p><p>In this study, the authors use a belief propagation (BP) algorithm to construct a network model of nearly 100 (phospho)proteins and several phenotypes in response to single and paired drug treatments. The network models use a differential equation framework, so they can be simulated to predict the response of the observed variables (proteins, phenotypes, etc.) to new perturbations and arbitrary combinations of perturbations. Simulations nominate c-Myc, which was not perturbed in the original drug screen, due to its in silico effect on G1 arrest. c-Myc is targeted indirectly with JQ1, and JQ1 in combination with predicted complementary inhibitors (MEKi and RAFi) induce strong changes in viability and G1 arrest.</p><p>The modeling approach is inherently limited to make predictions about proteins on the protein array in the perturbation screen and edges represent indirect effects, but the experimental/computational technique – in particular the focus on quantitative, predictive instead of descriptive networks – is powerful when there is sufficient coverage on the protein array. The algorithmic innovations have already been published (BP algorithm and preliminary SkMel-133 analysis in Molinelli 2013; including prior knowledge in Miller 2013). This manuscript expands the (phospho)protein antibodies (16 to 138), perturbation conditions (44 to 89), and phenotypes (1 to 5) modeled in RAFi-resistant SkMel-133 cells and evaluates new predicted pairs of inhibitors. It also introduces the pre-processing PERA step, which improves the inclusion of prior pathway knowledge by making it more systematic. The prior implementation – using soft constraints and rewarding edges with prior support instead of penalizing those without – is well-motivated given that interactions in pathway databases are derived from different cell types.</p><p>1) The criteria used to select c-Myc and G1 arrest instead of other phenotypes and top-ranked in silico perturbations are not made explicit, making it difficult to assess how well the method could predict additional novel perturbations. <xref ref-type="fig" rid="fig5s2">Figure 5–figure supplement 2</xref> shows that the top perturbation for all phenotypes is not novel but rather one of the activity nodes for the originally screened drugs. c-Myc does cause a substantial change to G1 arrest in silico, but so do other novel perturbations like p38 on viability, STAT3pY705 on S arrest, etc. Furthermore, it appears that there was no preference given to combinations of drugs that are predicted to be synergistic (similar to Miller 2013) or take effect at the lowest possible doses. Indeed, the top viability perturbations – PKCi and CDK4i – only reduced viability at high doses.</p><p>2) Is the RAFi-resistance phenotype of the SkMel-133 cell line recapitulated in the computational model? bRAF or aBRAF are top 10 predicted perturbations for all phenotypes except G2 arrest.</p><p>3) Are the observed changes in G1 arrest under inhibitor treatment statistically significant?</p><p>4) What was done to verify the identity of the SkMel-133 cell line?</p><p>5) Edge frequencies are one way to assess BP stability, and <xref ref-type="fig" rid="fig4s2">Figure 4–figure supplement 2</xref> shows that there are few stable edges. How much do the phenotype predictions vary across the 4000 simulations?</p><p>[Minor comments not shown.]</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.04640.031</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>The editorial team has identified two areas of major concern: (1) novelty of the approach and (2) biological significance</italic>.</p><p>We included two new sections to address these concerns (please see below).</p><p><italic>Regarding novelty of the approach, a portion of the most interesting methodological innovations has been already published by a subset of the authors. The pre-processing PERA step is new, and so are a number of other technical advances. In this paper, the authors extended the scope of the analysis substantially (phosphoprotein antibodies from 16 to 138, perturbation conditions from 44 to 89, and phenotypes from 1 to 5), and we appreciate that this extension is critical for biologists to adopt such approaches. However, the authors fail to clearly present the innovations over previous work. The authors should make an effort, perhaps in a dedicated subsection under Methods, to offer a nuanced discussion of the approach stating how it supports scientific discovery, what is novel relative to the earlier studies, and what are the open challenges. Overall the approach is technically solid and well-motivated, and</italic> eLife <italic>readers will benefit from such a discussion in the context of the new and extensive data set</italic>.</p><p>We included a detailed discussion of the methodological innovations, open challenges and significance of the method for scientific discovery. This is a separate section titled “Advances in the perturbation biology method” in Methods.</p><p><italic>Regarding biological significance, the reviewers all agree that the authors do not clearly address how their results advance our understanding of the biology, nor provide any novel biological insights. It is very important for</italic> eLife <italic>that any conceptual novelty is highlighted in the revised manuscript</italic>.</p><p>We rewrote a significant portion of the Discussion to better address the significance of our biological findings and their importance for cancer research, melanoma and drug resistance. In this section, we summarized:</p><p>A) The previous attempts (drug combinations) to overcome the drug resistance in melanoma.</p><p>B) Why targeting c-Myc and the ERK pathway is potentially more beneficial than other combinatorial interventions in melanoma.</p><p>C) A more generalized view of overcoming drug resistance by co-targeting upstream genomic aberrations and downstream signaling proteins, which are connected to diverse pathways.</p><p>D) The details of our findings in terms of synergistic response to BET bromodomain inhibitors and ERK pathway inhibitors.</p><p>E) Potential clinical applications of BET bromodomain inhibitors either as a single agent or in combination with kinase inhibitors (e.g., RAF-inhibitor) in cancer therapy.</p><p><italic>Other serious concerns include limitations of the approach with respect to predictions (reviewer 2, please address this in the response and in the manuscript), and lack of a convincing statistical validation (e.g., frequentist coverage of the predictions in a realistic simulation study – where data are generated using parameters estimated from the real data). We would like to see these addressed in the revision as well</italic>.</p><p>For limitations of the approach with respect to predictions, please see the response to reviewer 2.</p><p>For statistical validation, we computed the frequentist coverage probabilities of our predictions (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3–figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1E</xref>) for all cross validation predictions (CVs). First, we expanded the leave-11-out cross-validation (CV) simulations from 2 (AKTi and RAFi in <xref ref-type="fig" rid="fig3">Figure 3</xref>) to all possible conditions (2+10 calculations, <xref ref-type="fig" rid="fig3s1">Figure 3–figure supplement 1</xref>). Next, for each cross-validation/simulation set, we provided the frequentist coverage probabilities in 95%, 90% and 70% confidence intervals (CI) (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1F</xref>). The statistical validations show that in 10 out 12 of leave-11-out CVs, the frequentist coverage is &gt; 95%. For CV that involves the prediction of response to HDACi, the frequentist coverage probability is 93% for the 95% CI. We concluded that this is also a high-quality prediction given the level of ambition in our cross validation scheme. However, the frequentist coverage for CDK4i predictions is below 95% (88%). Indeed, the correlation coefficient between the simulated values and the hidden experimental conditions was also ∼0.70 for CDK4i, while the correlation coefficients are as high as 0.88 for other inhibitors. This is most probably due to the fact that the CDK4 inhibitor was highly toxic compared to the other compounds. The number of viable cells under CDK4i was lower than those in other perturbation conditions. Therefore, the prediction quality for CDK4i cross-validation was lower compared to the other CVs. Although we state that a predictive power of 0.70 is still sufficient to make useful predictions, this demonstrates the importance of a high quality training dataset for reaching excellent predictive power such as in all other conditions.</p><p><italic>Overall, this is a solid piece of work, and we look forward to receiving a revision.</italic></p><p>Reviewer #1:</p><p><italic>Conceptual and high-level feedback</italic>:</p><p><italic>In my opinion, the most significant and general result of this work is showing the promise of genomically-informed preclinical trials and providing a concrete example of a synergistic pharmacological treatment inhibiting the cell division of melanoma cells. The experimental design and the network inference methodology seem careful and well executed. The results appear convincing. On the down-side, I do not see much conceptual novelty or results contributing to our understanding of the biology. It is also not clear to me that the initial synergistic effect of co-targeting, which is interesting and explored in details, will actually prevent the development of drug-resistance over the long term in a clinical application. I invite the authors to emphasize any conceptual advances in their work and new biological conclusions that I may be missing. I think that conceptual advances would contribute the most to elevating the significance and general interest in this work</italic>.</p><p>We thank the reviewer for this suggestion and we believe this will certainly increase the significance of our study. As stated above, we have included two separate sections to address this issue: (1) we updated the Discussion section and described in detail the biological significance of our findings and the importance of the discovered combination strategy for RAFi resistance problem in melanoma biology; (2) we included another section to the Methods, where we discuss in detail the methodological improvements in this paper, how it can accelerate the biological discoveries and what the current open challenges are.</p><p>Reviewer #2:</p><p><italic>1) The criteria used to select c-Myc and G1 arrest instead of other phenotypes and top-ranked in silico perturbations are not made explicit, making it difficult to assess how well the method could predict additional novel perturbations.</italic> <xref ref-type="fig" rid="fig5s2"><italic>Figure 5–figure supplement 2</italic></xref> <italic>shows that the top perturbation for all phenotypes is not novel but rather one of the activity nodes for the originally screened drugs. c-Myc does cause a substantial change to G1 arrest in silico, but so do other novel perturbations like p38 on viability, STAT3pY705 on S arrest, etc. Furthermore, it appears that there was no preference given to combinations of drugs that are predicted to be synergistic (similar to Miller 2013) or take effect at the lowest possible doses. Indeed, the top viability perturbations – PKCi and CDK4i – only reduced viability at high doses</italic>.</p><p>We ranked the perturbation conditions based on their predicted influence on each phenotype in the model. We selected the top ranked perturbations as candidates for further experimental validation. One of the strengths of our method is that there is not a single but a set of useful (top ranked) predicted combinatorial perturbations in a given context (e.g., RAFi resistant melanoma cells). Each of these predictions can be tested using targeted drugs or other systems such as shRNA, CRISPR-Cas. We believe that these predictions will be a very useful resource for experimental biology groups that aim to test drug combinations in melanoma. We now have provided the predicted response to all the combinatorial perturbations on our webpage. Biologists can explore the predicted responses to &gt; 70000 combinatorial perturbations (combinations of different doses, strengths etc.) for five phenotypes. We also provide all of the model solutions so that they can predict response to alternative combination schemes (e.g., high order combinations, time staggered combinations etc.) using any type of program that can execute ODEs.</p><p>In this study, we chose to experimentally test one of the most promising predicted combinations: c-Myc/ERK-pathway (MEKi or RAFi) and G1 arrest. Reasons for selecting this combination include: (1) we predicted a substantial synergy for these combinations and these are the top responding targets for G1-arrest; (2) the combinations involve targets (e.g., ERK pathway) that are known targets for treatment of melanoma (3) induction of G1-arrest is a promising strategy for controlling melanoma growth (Solit et al., Nature, 439, 358-362); and various genes and cell cycle pathways associated with G1-arrest are involved in melanoma progression and RAF-inhibitor resistance (<xref ref-type="bibr" rid="bib51">Rother and Jones, 2009</xref>; <xref ref-type="bibr" rid="bib67">Xing et al., 2012</xref>). Such genes involve RB, CDKN2A &amp; CDKN2B (deleted in SkMel133 cells), CDK4 and many others (4) the predicted targets are potentially druggable, albeit indirectly in the case of c-Myc. We provide further details related to other predicted combinations below.</p><p>There are certainly other very promising predictions, such as targeting p-cJUN (Using JNK inhibitors) and ERK pathway for G1-arrest.</p><p>Some of the predicted perturbations/targets (activity nodes) were already included in the experimental training set. Combinatorial perturbations that involve such trivial and other novel/nontrivial targets should still be tested in the laboratory. One example is the HDAC inhibitor that induces a strong G2-arrest. It will be interesting to search for useful combinations involving HDACi. Some predicted targets are not “activity nodes” (e.g., STAT3pY705) and are less interesting than others since they are highly related to the activity nodes (i.e., perturbations). For example, STAT3i is already in the experimental set and it reduces both STAT3 phosphorylation (STAT3pY705) and cell viability. Therefore it was not an immediate choice for us. Interestingly p53 and aMDM2 have very similar G2-arrest responses (<xref ref-type="fig" rid="fig5s2">Figure 5–figure supplement 2</xref>). Note that MDM2 is a p53-specific ubiquitin ligase and controls p53 stability.</p><p>Some of the predicted targets are not directly druggable with targeted compounds (e.g., most total level targets, such as p38/MAPK14, p27/Kip1, CRAF, TSC2, caveolin). New gene editing technologies such as CRISPR may be useful to experimentally perturb these nodes and test our predictions.</p><p>We provide a very brief summary of the above in the revised manuscript (Results, last paragraph). We also included a table that lists the top predictions (<xref ref-type="supplementary-material" rid="SD1-data">Supplementary file 1</xref>).</p><p><italic>2) Is the RAFi-resistance phenotype of the SkMel-133 cell line recapitulated in the computational model? bRAF or aBRAF are top 10 predicted perturbations for all phenotypes except G2 arrest.</italic></p><p>The RAF-inhibitor resistance was recapitulated in the computational models. A good measure of the RAF-inhibitor resistance in the models is the response to perturbation on the aBRAF but not the BRAF. The BRAF node corresponds to the total protein level of the BRAF protein and aBRAF is an activity node that couples the effect of the RAF inhibitor to rest of the network.</p><p>aBRAF is in the top 10 predictions only for G1-arrest. The experimental phenotypic response data (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) show a slight G1-arrest response to MEK and RAF inhibitors (Note that RAFi/MEKi combination does not lead to a drastic increase G1-arrest. Also see the strong G2-arrest response to HDACi, which was recapitulated in the models; <xref ref-type="fig" rid="fig5s2">Figure 5–figure supplement 2</xref>). These effects are recapitulated in the models as aBRAF is in top 10 for the G1-arrest prediction. However, as can be seen in <xref ref-type="fig" rid="fig6">Figure 6A</xref>, the response to combined targeting of c-Myc, CyclinD1, aMEK, aBRAF and p-cJun is higher than the single agent perturbations. aBRAF was not in the top10 predictions for other phenotypes.</p><p>The total BRAF level is in the top 10 for cell viability, S-arrest and G2M nodes but the predictions do not suggest that BRAF has a drastic effect on any of the phenotypes (compared to the top few predictions). According to the vast literature on RAF inhibitors and melanoma, the total BRAF level usually does not immediately change in response to RAF inhibition and is not a direct measure of RAFi resistance, as RAFi inhibits phosphorylation of MEK by mutated BRAF protein. However, it is very interesting that BRAF (and CRAF) levels are related to cell viability and some of the cell cycle phenotypes. It is reported that the long-term changes in expression levels and heterodimerization of BRAF and CRAF have nontrivial implications in the emergence of resistance to RAF inhibitors (See <xref ref-type="fig" rid="fig2">Figure 2</xref> in Lito, Rosen and Solit, 2013, Tumor adaptation and resistance to RAF inhibitors, Nature Medicine). Due to the transactivation of the wild-type BRAF and CRAF and RAF isoform switching in response to RAF inhibition, the relation between the (B/C)RAF concentration and drug resistance is not linear. Experimentally testing the effect of changes in BRAF/CRAF on RAF inhibitor-induced phenotypes and RAFi sensitivity will be very interesting. On the other hand, we did not perform experimental tests related to predictions on RAF levels. In the current manuscript, it would not be more than a speculation to relate (B/C)RAF levels and drug resistance.</p><p><italic>3) Are the observed changes in G1 arrest under inhibitor treatment statistically significant?</italic></p><p>Cell cycle arrest experiments (flow cytometry) were run in triplicates. Although we refrained from running a t-test with three data points, we provided standard error bars in <xref ref-type="fig" rid="fig6">Figure 6D</xref>. The error bars indicate that the G1 arrest response for the combination is significantly stronger than those for other conditions (no drug and single drug perturbations).</p><p><italic>4) What was done to verify the identity of the SkMel-133 cell line?</italic></p><p>Our collaborators and co-authors, David Solit and Christine Pratilas, verified the identity of the SkMel133 and a panel of other melanoma cell lines. They checked for mislabeling, contamination and misidentification using a multiplexed PCR/mass spectrometry (MS)–based genetic fingerprinting assay run on the HapMap Sequenom platform. The method is described in: Janakiraman et al., Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer, Cancer Res. 2010 Jul 15;70(14):5901-11. We now state this in the Methods section of the revised manuscript.</p><p><italic>5) Edge frequencies are one way to assess BP stability, and</italic> <xref ref-type="fig" rid="fig4s2"><italic>Figure 4–figure supplement 2</italic></xref> <italic>shows that there are few stable edges. How much do the phenotype predictions vary across the 4000 simulations?</italic></p><p>We now provide the distributions of all the predicted responses over 4000 solutions on our webpage (<ext-link ext-link-type="uri" xlink:href="http://130.211.159.201/pertbio/">http://130.211.159.201/pertbio/</ext-link>). The statistical information for each distribution is also provided on the webpage.</p></body></sub-article></article>